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CHAPTER 1. INTRODUCTION AND BACKGROUND 
1.1 Statement of purpose 
This dissertation aims to contribute to the body of knowledge on breast cancer incidence 
patterns, diagnosis and treatment outcomes in Ghana and the United States (US). The 
aims of this dissertation research are to:  
1. Examine Ghanaian women’s pathways from breast cancer-related symptom 
detection through treatment receipt;  
2. Assess factors explaining the younger age at breast cancer diagnosis in Ghana 
compared to the US; 
3. Evaluate whether there is a survival advantage to a more aggressive surgical 
approach for treating triple negative breast cancer (TNBC). 
Findings from this study will help improve breast cancer early detection and treatment 
interventions in Ghana and the US.   
1.2 Specific aims  
Breast cancer is the most commonly diagnosed cancer among women worldwide. 
In 2020, there were approximately 2.3 million new cases of breast cancer and breast 
cancer accounted for 1 in 6 cancer deaths among women (1). Breast cancer is a 
heterogeneous disease that is classified into subtypes based on estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) 
expression patterns. The subtypes include luminal A, luminal B, triple negative (TNBC), 
and HER2-enriched (2). In the US, TNBC accounts for 12-15% of all invasive breast 
cancers but has the highest recurrence rate and lowest survival rate compared to the other 
subtypes (3, 4). Black women in the US and West African countries like Ghana are more 
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likely to be diagnosed with this aggressive subtype of breast cancer (5). There is an 
urgent need for research to inform breast cancer early detection and timely treatment 
strategies among Black women in the US and Ghana. 
More than fifty percent of breast cancer patients in Ghana are diagnosed at 
advanced stages with metastatic disease. Most breast cancer patients in Ghana are 
diagnosed with advanced metastatic disease due to delays in formal diagnosis (6). No 
study has traced in detail Ghanaian breast cancer patients’ pathways from symptom 
detection to treatment initiation. An understanding of how Ghanaian women navigate the 
healthcare system and factors that influence their decisions and ability to seek and access 
breast cancer care is essential for developing interventions aimed at improving early 
breast cancer detection, obtaining timely treatment and thus reducing breast cancer 
related mortality.  
Several studies show that Ghanaian breast cancer patients tend to be younger than 
patients in other parts of the world. For example, the median age at breast cancer 
diagnosis among women in Ghana is 48 years, compared to 60 years among Black 
women and 63 years among White women in the US (7, 8). Worldwide, breast cancer in 
younger patients tends to be more aggressive with rapid progression compared to older 
women (9). Particularly in an under-resourced healthcare setting, such as Ghana, it is 
critical to assess factors explaining the younger age at diagnosis in order to inform 
screening and treatment guidelines. Reasons for younger age at diagnosis are conflicting. 
Some studies suggest that the young age profile is due to biological differences while 
others suggest that it is due to differences in population age structures between countries 
(10, 11). However, these competing hypotheses have not been well explored. 
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Recommended surgical treatment for TNBC is either mastectomy or breast 
conserving surgery (BCS). Either surgical option can be followed by radiation therapy 
(12). Targeted therapies such as trastuzumab cannot be used in the treatment TNBC since 
it lacks ER, PR and HER2 receptors (13). The poor prognosis of TNBC contributes to the 
controversy regarding whether mastectomy (the most aggressive surgical approach) is a 
more appropriate surgical treatment for TNBC than breast conserving surgery (BCS) 
(14). Given the aggressive nature of TNBC, it is essential to use real world data to 
examine the most optimal surgical treatment for patients with TNBC. 
1.3 Background 
1.3.1 Breast cancer subtypes 
 
Breast cancer is grouped into four subtypes based on estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) 
expression patterns. Immunohistochemistry (IHC) is used to identify ER and/or PR 
expression while IHC and/or fluorescence in situ hybridization (FISH) is used to identify 
HER2. The four subtypes are luminal A, luminal B, TNBC and HER2 enriched (2). The 
different subtypes have different clinical features, which affect treatment responses 
therefore therapeutic strategies should be tailored by subtype. In the US, luminal A 
subtype is the most common subtype and has the best prognosis (3). TNBC accounts for 
12-15% of all invasive breast cancers but has the worst prognosis (13). For example, the 
10-year disease-free survival for Luminal A is approximately 86% while that of TNBC is 





Table 1: Breast cancer subtypes by estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (HER2) expression patterns and 
prevalence in the US.  
 
Breast cancer subtype ER,PR,HER2 status Prevalence in the US (15, 16) 
Luminal A ER+, PR+, HER2- 50%-60% 
Luminal B ER+, PR+, HER2+ 15%-20% 
HER 2 enriched ER-, PR-, HER2+ 15%-20% 
Triple Negative 
(TNBC) 
ER-, PR-, HER2- 12%-15% 
 
Breast cancer subtypes in the US vary by race/ethnicity. Luminal A is most common 
among White women while TNBC is most common among Black women (17)(17).  
 
 
1.3.2 Risk factors for breast cancer  
 
Risk factors for breast cancer include reproductive, hormonal and genetic factors. 
Early age at menarche (18), late onset of natural menopause (18), late age at first 
childbirth and low parity (19) increase the risk for breast cancer. High body mass index 
(BMI) (20) and use of hormone replacement therapy  (21) are associated with increased 
risk of breast cancer. In addition, women with high breast density (22) and family history 
of breast cancer (23) have an increased risk of breast cancer. Lastly, women who have 
BReast Cancer genes 1 and 2 (BRACA1 and BRACA2) are at an increased risk of breast 
cancer (24). BRACA 1 gene is also associated with increased risk of TNBC (25). 
1.3.3 Breast cancer treatment 
 
Mastectomy or breast conserving surgery (BCS) are the two surgical treatment 
options for early-staged breast cancer. Either surgical option can be followed by radiation 
therapy (12). The surgical treatment is determined by the nodes involved and tumor size 
but guidelines do not classify surgical treatment by breast subtype (26). Systemic therapy 
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which is determined by breast cancer subtype, includes chemotherapy and endocrine 
therapy. Recommended treatment for early staged TNBC is surgery with or without 
radiation and chemotherapy. Chemotherapy is the recommended treatment for metastatic 
TNBC  (27).  
1.3.4 Breast cancer burden in the US 
 
Breast cancer is the most common cancer and the second leading cause of cancer 
death among women in the US. The incidence of breast cancer is approximately 127.5 
per 100,000 women per year while the mortality is approximately 20.6 per 100,000 
women per year (8). Breast cancer incidence has been increasing by about 0.3% per year 
over the last 10 years while mortality has been decreasing by about 1.8% due to advances 
in treatment (28). However, there are persistent racial disparities. Compared to White 
women, Black women have lower incidence of breast cancer (130.5 per 100,000 vs 124 
per 100,000 persons respectively) but they have higher mortality rates (20.1 per 100,000 
vs 28.1 per 100,000 respectively) (8). These disparities are largely driven by 
discrimination and racism in accessing breast cancer care. For example, lack or limited 
health insurance and access to primary care clinics increases the probability of Black 
women being diagnosed at a late-stage which is associated with lower survival rates (29).   
1.3.5 Breast cancer burden in Ghana  
 
The lack of population-based cancer registries in SSA limits the ability to 
accurately assess the burden and characteristics of cancer cases. Most of the breast cancer 
studies in Ghana are hospital based and incidence rates are based on the International 
Association of Cancer Registries (IARC) GLOBOCAN database (30). According to 
IARC GLOBOCAN database, the age standardized incidence rate of breast cancer in 
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Ghana is 43.0 per 100,000 and the mortality rate 17.7 per 100,000 (31). In terms of 
demographic and clinical characteristics, breast cancer patients in Ghana are more likely 
to be pre-menopausal (32, 33), have had children (6, 32) and are younger (incidence 
peaks between 40-50 years) (7, 34-36). Further, most patients are diagnosed with 
advanced metastatic disease (6, 32), are more likely to have TNBC (36, 37) and 




CHAPTER 2. MANUSCRIPT 1: PATHWAYS TO BREAST CANCER 
DIAGNOSIS AND TREATMENT AMONG WOMEN IN GHANA: A 
QUALITATIVE STUDY.  
 
 
2.1 Introduction  
Breast cancer is the leading cause of cancer death among women worldwide. In 
sub-Saharan Africa, breast cancer represents 25% of the total cancer burden making it the 
most common cancer and leading cause of cancer deaths among women (38). Breast 
cancer is the most common cancer among women in Ghana with an age standardized 
incidence rate of 43.0 per 100,000 (31). 
Most breast cancer patients in Ghana are diagnosed with advanced metastatic 
disease due to delays in formal diagnosis. Several studies report that time from symptom 
onset to diagnosis and treatment receipt varies substantially in Ghana. In one study, time 
between detecting a symptom and reporting to a hospital ranged from one week to 5 
years(39) while another study reported an average of 10.8 months between symptom 
detection and diagnosis (40). Dedey et al. found that the median time between a breast 
cancer diagnosis and start of definitive treatment was 5 weeks (41). Factors associated 
with these diagnostic and treatment delays included misdiagnosis in previous medical 
consultation, financial constraints, lower level of education, older age, not married and 
lack of adequate information from the healthcare workers (39, 41).  
Ghana, like most sub-Saharan African countries, lacks a national breast cancer screening 
program. Thus most women seek breast cancer care once they identify symptoms (39). 
The women then have to navigate the healthcare system to get diagnosed and receive 
treatment. To our knowledge only one study, based in Malawi, has detailed women’s 
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specific pathways to breast cancer diagnosis and treatment in sub-Saharan Africa (42). 
Three studies set in Ghana have described some aspects of the breast cancer care seeking 
pathway in Ghana. Two studies described women’s symptom recognition, appraisal and 
intent to seek medical care, while the third described the diagnosis and treatment 
procedures (40, 43, 44). However, no study has outlined in detail the pathways that 
women in Ghana navigate from symptom detection through treatment receipt. 
Understanding this full process and appreciating women’s understanding and needs is 
essential if effective interventions are to be developed. 
The objective of this study is to explore Ghanaian women’s pathways from breast 
cancer-related symptom detection to treatment. Our definition of the term ‘pathways’ is 
guided by the Model of Pathways to Treatment Framework (45). We define pathways as 
the sequence of events and processes in a woman’s journey from breast cancer-related 
symptom(s) detection to treatment receipt. According to the Model of Pathways to 
Treatment Framework, events are the “key time periods” while processes are the 
“cognitive, emotional, behavioral, organizational or structural actions” in the woman’s 
journey to treatment receipt (45). Based on the findings from the interviews, we present a 
framework showing specific steps in the pathways and how women transition from one 
step to another.  
2.2 Materials and Methods  
2.2.1 Theoretical framework  
The Model of Pathways to Treatment framework informed our study development 
and analysis (45). The model has four intervals: appraisal, help seeking, diagnostic and 
pre-treatment. The appraisal interval is the time between discovering a symptom and 
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perceiving reason to seek help from a health care provider. Help-seeking interval is the 
time-period between perceiving reason to seek help from a healthcare provider to visiting 
a healthcare provider. In our study we combined the appraisal and help-seeking intervals 
to form the detection interval. This was based on similar breast cancer studies which have 
found it challenging to distinguish appraisal and help-seeking intervals (46). The 
diagnostic interval is the time between seeing a healthcare provider and being diagnosed 
cancer. The pre-treatment interval is the period between getting diagnosed and starting 
treatment. We also added the treatment interval in order to have a comprehensive 
understanding of the care continuum (45). 
 
2.2.2 Study Design and Setting  
An empirical phenomenological approach was used to explore the pathways of women 
diagnosed with breast cancer from the moment they detected symptoms to treatment. 
Phenomenology is used to describe and understand the lived experiences of a group of 
individuals grounded in the individuals’ description and meaning (47). The aim of our 
study was to describe the perspectives and experiences of our research participants from 
breast cancer-related symptom detection through treatment receipt. Given our interest in 
describing the phenomenon of navigating breast cancer diagnosis and treatment processes 
and from the perspective of our study participants, a phenomenological approach was the 
best fit for our study. This study was conducted in Kumasi, Ghana. Participants were 
recruited from the Komfo Anokye Teaching Hospital (KATH) Oncology Department. 
KATH is the second largest hospital in Ghana and the main cancer management hospital 
in the Ashanti region of Ghana.  
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2.2.3 Study Population, Sampling and Sample Size  
Eligible participants were women (18 years and older) with a histopathology confirmed 
diagnosis of breast cancer, who had started receiving at least one breast cancer treatment 
(surgery, chemotherapy or radiotherapy), could speak Twi (local language), and were in a 
stable condition at the time of study. We reviewed the patients’ medical records to 
confirm diagnosis and treatment receipt. We used a purposive sampling technique(48) in 
order to enroll participants who had experienced the phenomenon under study, were 
willing to participate and could clearly communicate their breast cancer management 
experiences. Data saturation was determined from the interviews. We determined we had 
reached data saturation when data from new interviews tended to be redundant of the data 
we had already collected (49, 50).  
2.2.4 Recruitment 
A trained Research Assistant (RA) met the patients at the KATH Oncology department to 
assess eligibility and invite them to participate in the study. Specifically, the RA read to 
each potential participant the study information sheet which included the goals of the 
study, what is required of each participant and a reminder that participation was 
voluntary. The interviews were carried out between November 2019 and March 2020.  
2.2.5 Data collection  
A semi-structured interview guide was used for the interview. The guiding questions 
were based on previous similar publications(42, 46, 51-56) and were adapted for use in 
the Ghana context. Section 1 of the interview guide (Appendix A) was semi-structured, 
and it was based on the Model of Pathways to Treatment framework. Section 2 
(Appendix A) included patient demographics and was close-ended. All participants gave 
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consent by signing or thumb-printing. Interviews were carried out in Twi in a private 
room within the KATH Oncology department. We pre-tested the interview guide by 
interviewing three breast cancer patients from the Oncology department and a Ghanaian 
qualitative researcher with clinical experience in oncology (ABBM) reviewed the guiding 
questions for socio-cultural appropriateness. Based on the pre-test interviews and advice 
from ABBM we revised the order of the interview guide questions. The main guiding 
question was: Please tell us the story of your journey from when you detected bodily 
change to when you started receiving breast cancer treatment. We then used more 
specific follow up questions to further understand the events in each interval. Interviews 
lasted 42 minutes on average (range 19 – 84 minutes). 
2.2.6 Data Analysis 
Data collection and analysis were undertaken concurrently. All interviews were audio-
recorded to ensure we captured all the patient’s information and to enable transcription 
for subsequent analysis by independent analysts. At the end of each interview, the 
interviewer and one of the authors (EWM) reviewed the recording and saved it to a 
password protected laptop. All interviews were conducted in Twi and translated into 
English by a professional transcriber who is proficient in Twi and English. One of the 
authors who is proficient in Twi and English (ABBM) reviewed a random sample of the 
recordings and transcripts to ensure accuracy in interviewing, transcription and 
translation. We used NVivo 12plus(57) computer software to facilitate analysis 
organization.  
A deductive coding analytic process was used (58). We had a list of codes (‘start 
list’) based on the Model of Pathways to Treatment (45)  but we also created codes for 
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other concepts that emerged from the data and were not part of the start list. Two analysts 
(EWM and ABBM) independently coded the transcripts in three stages. For the first 
stage, they independently assigned codes to text sections based on the Model of Pathways 
to Treatment framework (45). For the second stage, they independently re-reviewed the 
data to identify emerging codes that were not part of the framework. They then discussed 
the codes, clarified discrepancies, revised definitions and created new codes. For the third 
stage the analysts jointly organized the codes into steps and themes guided by the Model 
of Pathways to Treatment Framework (45). The rest of the authors confirmed the 
findings. This in-depth analysis process ensured reliability of the results (59). 
2.2.7 Trustworthiness and credibility  
Credibility was achieved by triangulation(60) and member checking (61). Data source 
triangulation involved using information from the patient’s medical records at KATH to 
verify the procedures and treatments that the patients received. Analyst triangulation 
involved two of the authors (ABBM and EWM) comparing and discussing the analyses 
until consensus was achieved. After each interview, the RA gave a summary of the 
interview and asked the participant to confirm that the summary reflected their 
experiences. In addition, five participants independently reviewed their transcripts to 
affirm that they accurately reflected what they had shared. This was done within one 
week of transcription. None of the participants had concerns or reservations about the 
content of the interviews. Field notes, which included the participants’ non-verbal cues, 
concerns, and interviewers’ reflections, were recorded after each interview and referred 
to during the analysis. The two RAs who carried out the interviews are nurses by training, 
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thus have a clinical understanding of breast cancer. However, none of them work in the 
KATH Oncology department and had no direct relationship with the participants. 
Ethical approval was granted by the Institutional Review Boards at KATH (KATH-
IRB/AP/001/19) and University of Minnesota (STUDY00006750). In order to protect the 
patient’s identity, we assigned each participant a random number that was used in the 
transcripts. Audio records and transcripts (without any identifying information) were 
stored on a password-protected computer. We followed the Standards for Reporting 
Qualitative Research (62). 
 
2.3 Results  
We interviewed thirty-one women who were diagnosed with breast cancer between 2015 
and 2019. The mean age of the participants was 51 years. Most of the participants were 
married/partnered/cohabiting, Christians, had at least primary school education and had 
no family history of cancer. Of those who had a job (n=14), most of them were self-
employed. Thirty of the thirty-one participants had health insurance (Table 2).  
Table 2: Socio-demographic characteristics of the sample (N=31). 
Characteristic  N (%) 







Highest education level 
Primary School  
High School  














































We describe the pathway steps that emerged from each interval. The pathway was not 
linear and some patients looped back to earlier steps while some skipped some of the 




Figure 1: Pathway of care from symptom detection to treatment for breast cancer 
patients in Kumasi, Ghana. Dotted lines represent patients going back to previous steps. 




2.3.1 Detection interval  
 
The average time between symptom detection and seeking orthodox medicine was 11 
months. 
Step 1: Initial symptom recognition and appraisal  
Type of symptom and way of discovery 
All the women detected initial symptoms themselves. The most common initial symptom 
was lump (n=23). Other initial symptoms included swollen breast (n=3), fluid oozing 
from the breast nipple (n=2), burning sensation (n=1), rashes on the breast (n=1) and pain 
(n=1). Two of the women recognized the initial symptom while doing a self-breast exam, 
while the other twenty nine discovered them accidentally.  
“I was there one day and I examined my breast and I realized that there is a lump 
at the top.” (P21) 
 
“When I woke up in the morning, I wore a white nightie the previous night and I 
realized there was blood where my breast touched the fabric.” (P19). 
Initial symptom interpretation  
Only two women thought the initial symptom was due to breast cancer. Both of these 
women had aunts who died of breast cancer and one of them was a nurse, thus they were 
aware of breast cancer.  
“In my mind, I thought maybe I have been afflicted with breast cancer… because 
my mother’s sister had it.” (P3) 
“I felt the lump so I kept touching it. My mind went there….. [assuming it was due 
to breast cancer].” (P8) 
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The other twenty-nine women did not think the initial symptom was serious. Most of 
them thought it was a boil while others associated the symptoms to the menstrual cycle, 
insect bite, food they had eaten, or breast-feeding. 
“It was like Oh this is just like a lump…. I did not anticipate that it was serious or 
going to be breast cancer.” (P6).  
“Whenever I am about to have my menses, my breasts will swell up and become 
bigger… When I observed this change… I reasoned that it could be related to my 
menses. I did not perceive it serious.” (P11). 
Symptom disclosure  
The women disclosed their symptoms to individuals they trusted which included 
relatives, friends who were in the healthcare field, and work colleagues. Most of the 
people advised the women to go to the hospital for a checkup, others advised them to 
wait and monitor the symptoms while some advised them to see a traditional healer.  
 “And when I saw it [blood oozing from nipple], I informed a sister living in the 
same house. She advised going for herbal medicine.” (P19) 
“I showed it to three of my sisters…. It looked as if the breast was tilted…One of 
my sisters advised me to take it straight to [a district hospital] in the morning if I 
have insurance.” (P12)  
“There was a nurse in our house and…when I told her, she told me to wait for a 
while because it could be the result of the ‘sure’ [deodorant] I am using, so I 
should stop using it.” (P18) 
Step 2: Initial symptom management before seeking orthodox care  
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Only two patients sought orthodox medicine right after discovering the symptoms (i.e. 
Step 1 to Step 3) while the rest used alternative strategies to manage the symptoms (i.e. 
Step 1 to Step 2).  
Traditional herbal medicine  
Six women, most of whom thought the symptom was a boil, visited traditional 
healers for herbal medicine which they applied on the breast hoping the lump 
would disappear.  
“When it [lump] initially started, I bought some herbal medication...and… smear 
it on the place… I thought it was a boil and when I take the drugs, it will 
eliminate it.” (P12) 
“I considered the lump as one of the usual breast problems. So, I started treating 
it with herbal medications.” (P9) 
Self- medication  
Two women whose initial symptom was breast pain used over the counter medication to 
reduce the breast pain and stop the spread of the infection.  
“It was Ampiclox and Paracetamol that were helping me. So whenever I took 
these, then the pains would reduce a little…and stop the infection.” (P22) 
“My children…bought me some medication from the chemist to stop the breast 
pains.” (P32) 
Faith healing  
Two women who associated the symptoms to spiritual causes sought faith healing to 
manage the initial symptoms.   
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 “A friend introduced me to a prayer group and so I joined…I put [prayer group 
anointed] oil on it.” (P32) 
“I initially thought the breast heaviness was due to evil witches bedeviling me. So 
I went to my personal priest…and resorted to prayers.” (P26) 
Wait and see  
Nineteen women decided to monitor the symptoms since they were not disrupting their 
daily activities and they did not consider them serious enough to seek care.  
“So when I observed the lump, I decided to wait awhile…because it wasn’t 
causing me any pain. I could carry on my normal activities.” (P25).  
“I found the lump in August, I thought it was just an ordinary lump…. Hence I 
waited until around October but monitored the symptom alongside.” (P6) 
Step 3: Decision to seek orthodox medicine  
Eventually all the women decided to seek orthodox medicine (i.e. either Step 1 to Step 2 
or Step 2 to Step 3) due to a combination of the following factors 
Additional symptoms  
Ten women decided to seek allopathic medicine only when additional symptoms 
disrupted their daily activities. These additional symptoms included pain, lump 
enlargement, wound, increased breast swelling and liquid oozing from the breast.  
“The lump was tiny but later on, it was getting bigger and that was the reason 
that prompted me to come to [hospital].” (P27) 
“Since it started being painful I had to do away with the herbal treatment and 
report to the [hospital].” (P24) 
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Alternative therapy failure  
Some women decided to seek orthodox medicine when there was no improvement from 
the use of alternative therapy.  
“Later, I realized the lump was getting bigger and when I touch the breast, it was 
more painful… I couldn’t groom regularly…that was when I realized that I have 
to go to the hospital.” (P22).  
“When the lump appeared, we started treating it with herbal medications and it 
went down a bit and it reappeared a little worse…When the herbal medication did 
not work we brought it to [hospital].” (P9) 
Advice and pressure from social network 
Other patients sought orthodox medicine due to advice from their social network. The 
advice could have been immediately after the patient saw the initial symptom, after failed 
alternative therapy or after they had additional symptoms.  
 
“So when I told my husband, he said you are saying you have observed a 
lump…take it to the hospital”. (P18).  
“The moment I told them [friends about symptoms], they said ‘be quick and take 
it to the hospital because you don’t play around with diseases affecting the 
breast….’ And I rushed to the hospital.” (P7) 
2.3.2 Diagnostic interval  
 
The average time between reaching the first health facility and getting a breast cancer 
diagnosis was 6 months.   
Step 4a: Reach first health facility  
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The healthcare system in Ghana includes both private and public hospitals. The public 
healthcare structure comprises three main levels: health centers and district hospitals that 
provide basic health care, regional hospitals that provide secondary health care and 
teaching hospitals that provide tertiary care (63). The two major factors that influenced 
which initial health facility women sought care at were recommendation from social 
network and familiarity with the specific healthcare providers. Familiarity with specific 
healthcare providers could be due to information the women had heard from the media or 
where they sought regular medical care. Most women first sought medical care at health 
centers and district hospitals. Only eight women initially sought care at teaching 
hospitals. Three women initially sought care at one of the private hospitals. Once at the 
first healthcare facility, the women were examined and either a) referred for diagnostic 
evaluations (i.e. Step 4a to Step 5); or b) referred to a higher level facility that had breast 
cancer specialists (i.e. Step 4a to Step 4b); or c) misdiagnosed and went back home (i.e. 
Step 4a to Step 1). 
 
I felt the burning sensation and to [health center] who declared there was nothing 
wrong…I went back home (Patient 3).  
“And when we went there [district hospital] the doctor declared it to be a lump so 
we should go and take a scan and he will take it (the lump) out for me.” (Patient 
17) 
“I went to see the doctor [district hospital] and he told me that those who used to 
work on these kind of cases are no longer working at the hospital. So he called 
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another doctor at [tertiary hospital] and informed him that he is sending a patient 
to him…I started coming here [tertiary hospital].” (P30) 
Step 4b: Reach second health facility   
Once the women reached the second health facility, women were either a) referred for 
diagnostic evaluations (i.e. Step 4b to Step 5), or b) others went back home due to 
misdiagnosis (i.e. Step 4b to Step 1), or c) referred to a third higher level facility for 
diagnosis (i.e. Step 4b to Step 4c).   
“[At district hospital], they made me take a scan… And then later on, I was 
told...they wouldn’t be able to take care of me so I should come to [tertiary 
hospital].” (P12). 
“I went to the hospital [regional facility], and they told me ‘No, it is not anything’ 
so I should go home…Three weeks’ time, I went to [another facility] … for 
review. And when they checked, they said the thing [lump] was no longer there. 
And me too, I just relaxed and stayed at home.” (Patient 16). 
Step 4c: Reach third health facility 
One woman was referred to multiple facilities before she was diagnosed (i.e. Step 4a to 
4b to 5 to 4c).   
“I went back to the nurses [in a health center] who advised going to see the 
doctor [at district hospital]. He [doctor] said I should go to [private lab] and 
take a scan and bring it back to him. When I brought it back…the doctor 
recommended being transferred because of how advanced my situation was. He 
directed me to [regional hospital]. However, we didn’t go but came here instead 




Step 5: Diagnostic evaluations 
None of the hospitals, including the tertiary hospitals, had all the necessary diagnostic 
services available. Patients had to be referred to private laboratories for diagnostic 
procedures such as mammogram. This process involved the women going back and forth 
from the referring hospital to the diagnostic labs for sample collection and back to the 
hospital to present the results. 
“The staff of [tertiary hospital) required me to do a lot of labs… I was made to 
place my breast in a machine [mammogram] in [private lab] and I brought all the 
results back to them.” (P13) 
“Well, when I came to [tertiary hospital] he [doctor] gave us some tests and we 
took a very big picture [scans]. He also requested another test at [private lab]. I 
have even been to that place two times. And all the documents associated with 
these are there. And I can’t even count the numerous other tests I’ve done over 
here” (P5). 
“He [doctor] took a sample of the breast…then he asked that I take a scan of the 
breast. He also asked me to go to [private lab] where they put the breast in a 
machine (mammogram]” (P11). 
  
Step 6: Get diagnosed with breast cancer  
Eventually all women were diagnosed with breast cancer. Twenty women were 
diagnosed at tertiary hospitals, three women were diagnosed at private hospitals while the 
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rest were diagnosed at regional and district hospitals. At the diagnosing facility, the 
women were examined and if the provider was suspicious of breast cancer, they would 
order diagnostic evaluations for her. These evaluations included mammogram, CT scan 
and biopsy.  
 “I did the mammogram and then the ultra sound… then biopsy. It was the biopsy 
that proved it that it was cancerous cells.” (P6)  
“I did the breast scan mammogram and the tissue biopsy...and I went for the 
results and it they told me it was cancer” (P8) 
Of the women who had stage information, six had stage III disease, two had stage IV and 
two had stage II. Of the women who had breast subtype information, two had HER2 
enriched subtype, two had luminal A, and four had triple negative subtype. The women 
stated their initial reactions to the diagnosis included shock, fear of mastectomy and 
death, crying, and financial worry. However, others said they were not scared or worried 
as they leaned on their religious faith and encouragement from the doctor who delivered 
the diagnosis. Some patients continued to Step 7 while others went back to Step 1. 
2.3.3 Pre-treatment interval  
 
The average time between breast cancer diagnosis and starting treatment was 5 months.  
Step 7: Discussion at tumor board  
Komfo Anokye Teaching Hospital (KATH) tumor board group consists of surgeons, 
pathologists, oncologists, radiologists, and nurses. After diagnosis, all patients are 
discussed by the tumor board to determine the treatment course. Patients are encouraged 
to be present when their cases are being discussed if at all possible.  
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“The doctor scheduled me for a meeting [tumor board]. The nurse brought me to 
this meeting. So after they [tumor board members] had asked me a few questions, 
they discussed it and started me on the chemo.” (P28) 
“Following the diagnosis, we were scheduled for a meeting [tumor board] in two 
weeks. The doctor explained that everyone involved [at the tumor board] will 
bring their opinion …it is important for me to sit in during deliberations… 
However, the same doctor later told us not to come for the meeting due to my long 
distance, so he will represent me.” (P4) 
Step 8: Evaluations prior to starting treatment  
After breast cancer diagnosis, the women typically needed more laboratory testing before 
they started treatment.  
 “I had to finish my labs; the full blood count, the kidney function test and 
everything before they started the treatment.” (P8) 
“He requested I go for a lab test… they examined a lot of tissues They examine 
your blood; they check the blood to know if you can take the thing 
[chemotherapy]” (P23) 
2.3.4 Treatment interval  
 
Step 9: Start treatment  
The most common treatment course was neoadjuvant chemotherapy, followed by surgery 
followed by adjuvant chemotherapy and radiotherapy and hormone therapy. 
“I was given six injections of chemotherapy… then they took me to cut off the 
breast [mastectomy]. After the operation I was put on a machine [radiotherapy], 
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and after the machine, I was given a prescription for medication that I was buying 
[hormone therapy].” (P29) 
“I did four chemotherapy cycles before I was operated on. Then another four 




This study describes Ghanaian women’s paths from the moment they detect breast 
cancer-related symptoms through receipt of breast cancer treatment. To our knowledge, 
this is the first study to trace the breast cancer care pathway from Ghanaian women’s 
perspectives. Similar to Kohler at al.(42) study we found that the breast cancer pathway 
in Ghana is not linear. The Model of Pathways to Treatment framework(45) which we 
used to guide our data collection is built on an assumption that women only use orthodox 
medicine to manage their breast cancer. However, in our study we found that women 
frequently moved among different management approaches. We propose a modified 
framework (Figure 1) which is grounded in findings from our interviews with Ghanaian 
women with breast cancer.  
All the women discovered the symptoms themselves but only two women initially 
associated their symptoms with breast cancer. The rest thought their symptoms were not 
serious or could be easily managed by alternative therapies. This contributed to the 
substantially long average time of 11 months between detection symptoms and seeking 
orthodox medicine. The women in our study used different strategies to manage their 
breast cancer symptoms: traditional herbal medicine, over the counter medication, faith 
healing and wait and see if the symptoms went away. Wait and see was the most common 
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management strategy and involved the women monitoring their symptoms at home until 
they progressed to where the symptoms disrupted their ability to carry out daily activities. 
The main reasons for a wait and see approach were no pain associated with the symptom 
and interpretation that the symptoms were not serious and would resolve with time. This 
is consistent with previous research which has shown that women who have symptoms 
that are not associated with pain and who interpret symptoms as not serious are less likely 
to seek care immediately (54). 
The second most common symptom management strategy was seeking care from 
traditional herbalists and faith healers (alternative therapy providers). In our study, the 
women who sought alternative therapies assumed their symptoms were due to common 
ailments such as a boil or were caused by evil powers. Alternative therapy providers are 
more accessible thus are more often consulted for common ailments. They are also more 
trusted, compared to orthodox medicine providers, to treat diseases whose cause is 
associated with spiritual powers (64). Alternative therapy is commonly used in Ghana 
and other sub-Saharan African countries for cancer management (65). However, the 
literature typically describes alternative therapy as a barrier to early detection and timely 
orthodox medicine receipt (39, 42). In order to improve breast cancer management in this 
community, it is essential to acknowledge the critical role of alternative therapy in the 
breast cancer diagnosis and care pathways and develop approaches that integrate them 
into breast cancer diagnosis and management. In 2011, a plan for integrating alternative 
therapy and orthodox medicine for all diseases was launched in Ghana. However, there 
were no clear guidelines on what integration meant and how to go about it. For example, 
a study in one of the pilot hospitals for the integration found that patients who were 
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seeking care at the hospital were not even aware that herbal services were also being 
provided. In addition, the orthodox medicine providers at the pilot hospital perceived 
both systems to be parallel instead of integrated (66).  
There is potential for successful integration of alternative therapy providers in 
breast cancer management in Ghana. Faith healers and traditional herbal medicine 
providers in Ghana have expressed interest in working collaboratively with orthodox 
medicine providers (67, 68). Alternative therapy providers have previously been 
successfully integrated in HIV/AIDS and mental health care prevention and delivery (69, 
70). For the integration to be successful, there needs to be trust between orthodox and 
alternative therapy providers and an acknowledgement that both providers are 
complimentary (71). In an integrated system, alternative therapy providers can play two 
major roles: triage and offering psychosocial care and support. This may reduce the time 
between symptom detection and seeking orthodox medicine. In the triage role, alternative 
therapy providers would immediately refer women with breast cancer related symptoms 
to orthodox medicine. The psychosocial role of alternative therapy providers was also 
clear from our study where some women consulted with faith healers for emotional 
support after the diagnosis.  
All the women in our study detected the symptoms themselves. This is expected 
given Ghana does not have a national breast cancer screening program thus screening is 
ad hoc (39). However, there are non-governmental organizations (NGOs) in Ghana that 
organize clinical breast examinations (CBE). CBE is the physical examination by a 
healthcare provider to check for breast abnormalities (72). CBE has been shown to lead 
to significant breast cancer down staging (73). However, the CBE programs organized by 
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the NGOs in Ghana are sporadic which reduces their effectiveness. For example, one of 
the women in our study noticed the breast cancer related symptoms in August.  However, 
she was not aware of any hospitals that carried out breast cancer screening so she decided 
to wait for the annual October community breast cancer screening. For these programs to 
be effective, they need to be consistently available and women need to be aware of their 
locations.  
Given the challenges of implementing national screening programs, a more cost 
effective method to increase early diagnosis might be breast cancer awareness programs. 
Four women in our study sought medical care faster since they had learnt about breast 
cancer through the media and church events. In addition, a study in Ghana found that a 
community based breast cancer awareness program significantly improved women’s 
breast cancer knowledge and uptake of breast self-exam (74). Studies found that 60% of 
women in Ghana got health information from radio and television(75) and that mass 
media awareness is a cost effective intervention for increasing participation in breast 
cancer screening Ghana (76).  
Our study has several limitations. There is potential for selection bias. All our 
study participants were receiving breast cancer care thus we missed the experiences of 
women who never made it to the end of the breast cancer care pathway. Women who are 
not engaged in the cancer pathway may have had different experiences that we did not 
capture. However, we believe that the experiences of women who successfully navigated 
the various health care systems have insights that apply to those who were not successful. 
We asked women to remember all the steps that they took since symptom detection. 
Some of the women admitted they did not recall some of the events. Recall bias could 
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also impact our study. For example, women may not have mentioned that they sought 
alternative therapies at some point in their pathway due to stigma.  Strengths of our study 
include examining the pathway from the women’s perspective and use of medical records 
to confirm procedures and treatment. 
2.5 Conclusions 
 
Our study highlights that women go through approximately nine steps from symptom 
detection to receiving allopathic breast cancer treatment in Ghana. Some women skipped 
some of the steps while others looped back to earlier steps. At each step in the pathway, 
there are opportunities to intervene in order to increase the rate at which women are 
diagnosed and start receiving treatment. These interventions include integration of 
alternative therapy providers and allopathic medicine and consistent breast cancer 
awareness and clinical breast exam programs. Lastly, this breast cancer care pathway 
framework may be applicable to other cancers and other sub-Saharan African countries.  
CHAPTER 3. MANUSCRIPT 2: BREAST CANCER IN GHANA: WHY THE 
YOUNGER AGE AT DIAGNOSIS?  
 
3.1 Introduction  
 
Breast cancer is the most common cancer and leading cause of cancer deaths 
among women in sub-Saharan Africa (SSA). In 2020, breast cancer incidence rates in 
SSA ranged from 33 per 100,000 to 50 per 100,000 while mortality rates ranged from 18 
per 100,000 to 22 per 100,000 (1). Breast cancer patients in SSA tend to be younger 
(incidence peaks between 40-50 years)(7, 32, 77) than patients in other parts of the world 
such as the United States (US), where incidence peaks at approximately 62 years (8). 
Breast cancer among younger women (<40 years) tends to be more aggressive (higher 
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grade and larger tumor sizes) and have higher mortality rates compared to breast cancer 
among older women (≥40 years ) (78, 79). It is therefore essential to identify factors that 
can explain the younger age at diagnosis in SSA.  
Several studies suggest that the younger age profile in SSA compared to Europe 
and North America reflects differences in population age structures between countries 
(10, 11). For example, in Ghana, 35% of the population is between 25 and 59 years and 
only 4.7% of the population is above 65 years(80), while in the US 16% of the population 
is above 65 years (81). Therefore, breast cancer cases in Ghana are more likely to occur 
among younger age groups because a larger proportion of their at-risk population is in 
younger age groups. Bidoli and colleagues used data from 24 cancer registries in Eastern 
Mediterranean and Africa to explore the association between the median age at breast 
cancer diagnosis and the median age of the corresponding population (82). They found 
that the age at breast cancer diagnosis is associated with the age of the underlying 
population where a one year increase in population age was associated with 0.26 increase 
in median age at breast cancer onset. However, this study provided the association 
between median age at breast cancer diagnosis and median age of the population at the 
continental level where data from Africa and Eastern Mediterranean cancer registries 
were grouped together and did not adjust in detail for the age structure of any one 
country. Also, the study only included information from 24 cancer registries in the 
Eastern Mediterranean and Africa. Given the variation in cancer incidence rates between 
SSA countries, there is a need to understand factors contributing to country-specific 
breast cancer patterns (30).  
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Breast cancer screening may also impact a country’s average age at breast cancer 
diagnosis. Introduction of mammographic screening in the US is associated with an 
increase in breast cancer incidence rates among women 50 years and older and 
subsequent increase in median age at diagnosis (83). While most SSA countries, 
including Ghana, do not have a national breast cancer screening program, screening in 
the US is widespread (32, 84).  
Research has also shown that breast cancer incidence rates are on average lower 
in SSA compared to North America and Europe (5).  However, estimating cancer 
incidence rates in SSA is a challenge due to limited population-based cancer registries. In 
Ghana, only two studies have used population-based cancer registry data to assess the 
breast cancer incidence rates which were estimated at 7.9 per 100,000 in 2012 and 16.1 
per 100,000 in 2015 (7, 85). There is a need to better understand the breast cancer 
incidence patterns in Ghana.  
This study examines the impact of population age structure and breast cancer 
screening on the mean age at breast cancer diagnosis in Ghana and the US. We also 
examine the breast cancer incidence patterns in Ghana and the US between 2012 and 
2016. To achieve these aims we analyzed breast cancer data from the Kumasi Cancer 
Registry, the only population-based cancer registry in Ghana, and compare it to the US 








We obtained data on incident breast cancer cases in Ghana from the Kumasi 
Cancer Registry (KCR) and for the United States (US) from the Surveillance, 
Epidemiology and End Results (SEER) program. The KCR was established in 2004 as a 
hospital-based registry and was converted to a population-based registry in 2012 (7). The 
catchment area for the KCR is Kumasi which is the second largest city in Ghana and has 
a population of 2,035,064 (80). The cancer information in the registry is based on 
patients' medical records from six laboratories and five hospitals in Kumasi. One of the 
hospitals is the Komfo Anokye Teaching Hospital (KATH), which is the largest hospital 
in Kumasi and the second largest in Ghana (67). Information abstracted from medical 
records is reviewed and verified by a clinician and data quality monitored by the Registry 
Manager. A combination of date of birth, patient age, National Health Insurance number, 
and Hospital ID are used to create patient unique identifiers (7). 
SEER is a US database that includes cancer cases from population-based cancer 
registries that presently covers 34% of the US population and is representative of 
different racial/ethnic groups in the US (86). SEER collects information on incident 
cancer cases, key information about the tumors including stage at diagnosis, first course 
of treatment and survival (87). The SEER registries are grouped into three overlapping 
categories based on the years of data that the registries contribute: SEER 9, SEER 13 and 
SEER 18. SEER 9 includes cases diagnosed from 1975 to 2017 from nine cancer 
registries, SEER 13 includes cases diagnosed from 1992 to 2017 from the original nine 
registries plus four registries and, SEER 18 includes cases diagnosed from 2000 to 2017 
from an additional five cancer registries (88).  
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We obtained US population estimates stratified by race (White and Black), age 
(5-year age groups) and sex from the National Cancer Institute (89). The Kumasi 
population estimates stratified by age (5-year age groups) and sex were obtained from the 
Ghana Statistical Services (90). 
3.2.2 Breast cancer cases 
 
We included US and Ghanaian women diagnosed with invasive and in situ breast 
cancer with known age at diagnosis. For Ghana, we restricted to women diagnosed 
between 2012 and 2016 since these were the years that the KCR was population-based 
and had complete and accurate data. For the US, we included women diagnosed between 
2012 and 2016 to match the Ghana cohort and women diagnosed between 1975 and 1979 
to account for the effect of screening (more detail below). SEER 9 registries are the only 
ones that include cases diagnosed between 1975 and 1979 therefore we were limited to 
using the SEER 9 registries only. To ensure consistency, we also limited our US 2012-
2016 cancer diagnosis to those from the SEER 9 registries.  
3.2.3 Statistical Analysis  
 
Effect of population age structure on the differences in mean age at diagnosis between 
Ghana and the US  
We examined whether differences between Ghana and the US in mean age at 
breast cancer diagnosis persisted after accounting for differences between the two 
countries' population age structures. First, we calculated the crude mean age at diagnosis 
for Ghanaian and US female breast cancer patients diagnosed between 2012 and 2016. 
Research has shown that in the US, Black women are diagnosed with breast cancer at a 
younger age than White women, therefore we also calculated the crude mean age at 
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diagnosis by race (White vs Black) for the US population (91). Crude mean age was 
calculated as  
∑𝑦
∑𝑁
  where y is the age at diagnosis and N is the number of people with 
breast cancer. Second, to examine the effect of differences in population age structure 
between Ghana and the US, we calculated the adjusted mean age at diagnosis. We used 
the World Health Organization (WHO) world standard population as the standard 
population since it reflects the average age structure of the world’s population and 
facilitates comparisons with findings published from other countries (92). In the adjusted 
analysis, the weight was the proportion of people in the corresponding age group of the 




   where yi is the age at diagnosis and 𝑤𝑖 is the proportion of people in WHO 
standard world population for age yi. The adjusted mean age at diagnosis represents what 
the mean age at diagnosis would be if Ghana and the US had the same age population 
distribution. Third, age differences were calculated by subtracting the mean age at 
diagnosis among the US cases from the mean age at diagnosis among Ghanaian cases. 
Negative differences showed a lower mean age at diagnosis among cases in Ghana. We 
used a t-test to test whether the crude and adjusted mean ages between the two countries 
differ significantly.  
 
Effect of breast cancer screening on the differences in mean age at diagnosis between 
Ghana and the US  
We examined whether differences between Ghanaian and US women in mean age 
at breast cancer diagnosis persisted after accounting for breast cancer screening. SEER 
does not include screening information. Screening mammography was not nationally 
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adopted in the US until the 1980s, so we used data for US women diagnosed with breast 
cancer between 1975 and 1979 to adjust for the effect of screening mammography on the 
cancer incidence in the US (93). Specifically, we calculated crude mean age at diagnosis 
and adjusted mean age at diagnosis using the US SEER 9 1975-1979 breast cancer data. 
We then compared these values to the crude and adjusted mean age at diagnosis for 
Ghanaian women diagnosed with breast cancer between 2012 and 2016.  
Sensitivity analyses – impact of the standard population on the adjusted mean age at 
diagnosis 
We conducted a sensitivity analysis to assess the influence of using the WHO 
standard population on our estimates and conclusions. We calculated the adjusted mean 
age at diagnosis in the US and Ghana (as described above) using two standard 
populations: the US standard population and the European standard population. We then 
compared the estimates to those we had calculated using the WHO world standard 
population.  
Breast cancer incidence rates in Ghana and the US 2012 - 2016 
Lastly, we calculated and compared three breast cancer incidence rates in 2012-
2016 in Ghana and the US: crude, 5-year age-specific and age standardized incidence 
rates. The crude incidence rate is the number of new breast cancer cases for the period of 
interest as a proportion of the total population for the specific period. The 5-year age-
specific incidence rate is calculated as the new breast cancer cases in the 5-year age 
group as a proportion of the total population in the 5-year age group. The age 
standardized rates represent the incidence rate that would have been observed if Ghana 
and the US had the same age structure as the WHO world standard population. 
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All analyses used SAS (PC SAS 9.4, SAS Institute, Inc., Cary, NC). Ethical approval was 
granted by the Institutional Review Boards at KATH and University of Minnesota.  
 
3.3 Results  
 
Our dataset included 542 women from Ghana and 114,100 women from the US 
diagnosed with breast cancer between 2012 and 2016. Women were diagnosed at older 
ages in the US than in Ghana (Figure 2a, Figure 2b). Twenty-three percent of the 
women with breast cancer in Ghana were <40 years of age at diagnosis compared to four 
percent in the US. In the US, six percent of the Black women with breast cancer were 
<40 years of age at diagnosis compared to four percent White women. Only ten percent 
of the cases in Ghana were older than 70 years compared to twenty-eight percent of cases 
in the US, twenty-two percent of cases among Black women and thirty percent of cases 
among White women.  







Figure 2b: Age distribution for Ghanaian women and US Black and White women 
diagnosed with breast cancer 2012-2016  
  
 
Effect of population age structure on the differences in mean age at diagnosis between 
Ghana and the US  
Prior to adjustment, the mean age at diagnosis in Ghana was 50.3 years compared 
with 61.6 years among the US cases (crude difference of 11.3 years), which was 
significantly different (p<0.0001). After adjusting for population age structure, the mean 
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age at diagnosis remained significantly different between the two countries where the 
adjusted mean age in Ghana was 45.6 years and 55.1 years in the US (adjusted difference 
of 9.6 years, p <0.0001) (Table 3). 
After adjusting for population age structure, women diagnosed with breast cancer 
in Ghana were on average 8 years younger than Black women and 10.2 years younger 
than White women diagnosed with breast cancer in the US (Table 3).  
 
Effect of breast cancer screening on the differences in mean age at diagnosis between 
Ghana and the US  
To examine the combined impact of breast cancer screening and population age 
structure on the differences in mean age at breast cancer diagnosis between Ghana and 
the US, we compared 1975-1979 US breast cancer cases (before widespread breast 
cancer screening) to 2012-2016 Ghanaian breast cancer cases. Similar to the findings 
above, US women diagnosed with breast cancer between 1975 and 1979 were on average 
older than women in Ghana diagnosed with breast cancer between 2012 and 2016 
(Figures 3a and 3b, Table 4). However, the adjusted difference in mean age between 
2012-2016 Ghanaian and the 1975-1979 US breast cancer cases was smaller compared to 
the adjusted difference between 2012-2016 Ghanaian and the 2012-2016 US breast 
cancer cases (-8.0 years vs -9.6 years respectively). Even after accounting for screening 
and population age structure, a difference of -8 years remains between Ghana and the US 
(Tables 3 and 4).  
There was a similar trend when considering US White and Black cases separately. 
The adjusted difference in mean age between 2012-2016 Ghanaian cases and 1975-979 
US White cases was -8.5 years compared to -10.2 years when using 2012-2016 US White 
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cases. When we restricted to the US Black cases, the adjusted difference in mean age 
between 2012-2016 Ghanaian cases and 1975-1979 US Black cases decreased 
substantially from -8 years to -4.6 years(Tables 3 and 4).  
Figure 3a: Population age distribution for Ghanaian women diagnosed with breast 
cancer 2012-2016 and US women diagnosed with breast cancer 1975-1979 
 
Figure 3b: Age distribution for Ghanaian women diagnosed with breast cancer 2012-





Table 3: Mean age at diagnosis (crude and adjusted) for women 
diagnosed with breast cancer in Ghana and the US 2012-2016   
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Table 4: Mean age at diagnosis (crude and adjusted) for breast cancer cases 
diagnosed in Ghana in 2012-2016 and the US 1975-1979
 
 
Cases, N (%) Crude mean 





age (years) at 
diagnosis 
P value  
(T-test) 
Difference in 
mean (Ghana – 
US)  






















542 3258 50.3 56.2 <0.0001 45.6 50.1 <0.0001 -5.9 -4.6 
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  Sensitivity analyses – impact of the standard population on the adjusted mean age at diagnosis 
There were no notable changes in the adjusted mean age at diagnosis when we used the US and 
 European standard populations (Table 5). 
 









Ghana and US  breast cancer cases diagnosed 2012-2016 
 























542 144100 50.30 61.58 <0.0001 45.55 55.13 <0.0001 -11.28 -9.58 
United States 542 144100 50.30 61.58 <0.0001 46.46 56.18 <0.0001 -11.28 -9.72 
European 542 144100 50.30 61.58 <0.0001 47.01 56.16 <0.0001 -11.28 -9.15 
 
Ghana breast cancer cases diagnosed 2012-2016 and US cases diagnosed 1975-1979 
World Health 
Organization 
542 50496 50.30 60.63 <0.0001 45.55 53.58 <0.0001 -10.33 -8.03 
United States 542 50496 50.30 60.63 <0.0001 46.46 54.81 <0.0001 -10.33 -8.35 
European 542 50496 50.30 60.63 <0.0001 47.10 54.81 <0.0001 -10.33 -7.71 
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Breast cancer incidence rates in Ghana and the US 2012 – 2016 
Both the crude and age standardized breast cancer incidence rates were lower 
among Ghanaian women compared to US women between 2012 and 2016. The crude 
breast cancer incidence rate in Ghana was 9.15 per 100,000 and 189.14 per 100,000 in 
the US. The age standardized breast cancer incidence rates in Ghana were 14.16 per 
100,000 and 129.89 per 100,000 in the US. Age-specific incidence rates and the 
incidence rate differences between Ghana and the US increased with increasing age. 
Ghana's age specific incidence rate increases from 0.16 to 25.68 per 100,000, whereas the 
age specific rate for the US increases from 0.02 to 473.44 per 100,000.  In addition, 
Ghana’s incidence rate is 23.68 per 100,000 lower than the US’s in the 30-34 years age 
group and 408 per 100,000 lower in the 60-64 years age group. (Table 6).  
Table 6: Breast cancer incidence rates among women diagnosed with breast cancer 2012-
2016 in the US and Ghana 
  


















Age specific incidence rate/100,000 Difference 
(Ghana-
US) 
5 - 9  0.00 0.02 -0.02 
10 - 14  0.00 0.00 0.00 
15 - 19 0.16 0.10 0.06 
20 - 24 1.04 1.99 -0.95 
25 - 29  2.88 10.93 -8.05 
30 - 34 10.12 33.80 -23.68 
35 - 39 17.73 74.11 -56.38 
40 - 44 26.86 174.71 -147.85 
45 - 49  31.53 266.87 -235.34 
50 - 54 35.67 320.81 -285.14 
55 - 59 53.83 349.78 -295.95 
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60 - 64 34.59 442.59 -408.00 
65 - 69  39.37 546.54 -507.17 
70 - 74 23.20 591.61 -568.41 





In this population-based study of women diagnosed with breast cancer in Ghana 
and the US, we found that the mean age at breast cancer diagnosis is significantly lower 
among women in Ghana compared to the US. This discrepancy persisted even after 
accounting for differences between the two countries in population age structure and 
breast cancer screening. On average, women in Ghana were 11.3 years younger than 
women in the US. After adjusting for differences between the two countries’ population 
age and breast cancer screening, on average, women in Ghana were 8 years younger than 
women in the US at breast cancer diagnosis.   
In our study, the difference between Ghana and the US in mean age at breast 
cancer diagnosis for cases diagnosed 2012-2016 decreased from 11.3 years to 9.6 years 
after adjusting for differences between the two countries population age structure. Thus, 
15% of the difference in mean age at diagnosis between Ghana and the US is explained 
by these population age structure differences. A study by Bidoli et al. reported that age at 
breast cancer diagnosis reflects the median age of the population, where one year increase 
in population age was associated with 0.26 increase in median age at breast cancer onset 
(82). However, the differences in methods and populations between our study and Bidoli 
et al. make estimates from these two studies incommensurable. The Bidoli et al. study 
assumed a linear relationship, across registries in the Eastern Mediterranean and Africa, 
between median age of the population and the median age at breast cancer diagnosis 
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while we used direct standardization of the mean age at cancer diagnosis. Also, our study 
included and pertains only to the US and Ghana populations while Bidoli et al.'s analysis 
is at the continent level, combining data from the Eastern Mediterranean and Africa.  
We explored the possibility of breast cancer screening influencing the significant 
difference in the mean age at breast cancer diagnosis between Ghana and the US. Once 
we accounted for population age structure and screening effect, the difference in mean 
age at diagnosis between Ghana and the US decreased from 11.3 years to 8 years. This 
decrease is due to the fact that the mean age at diagnosis in the US was higher in the post-
screening era (2012-2106) compared to the pre-screening era (1975-1979). Screening 
mammography in the US has been associated with an increase in breast cancer incidence 
rates especially among women 50 years and older, the ages at which routine screening is 
recommended, resulting in an increased the mean and median age at diagnosis (83). In 
spite of the many advantages of breast cancer screening, it is well recognized that some 
cancer cases detected by screening are indolent and unlikely to progress to clinically 
significant disease (94). 
Even after taking into account differences in population age structures and 
screening, women in Ghana were 8 years younger at breast cancer diagnosis compared to 
women in the US. A possible explanation for this persisting difference in mean age at 
diagnosis is differences in the prevalence of risk factors among older women in Ghana 
compared to older women in the US. Older women in Ghana are more likely to have 
protective breast cancer risk profiles such as higher parity (95, 96) leading to a decreased 
breast cancer incidence rate among older women in Ghana compared to older women in 
the US. Consistent with this explanation, we observed that differences between Ghana 
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and the US in incidence of breast cancer increases with age. Specifically, at >=40 years, 
the incidence of breast cancer is substantially higher in the US compared to Ghana vs 
incidence rates at <40 years. This observation is similar to a previous study that found 
breast cancer incidence rates among women <40 years in North-Africa and France were 
similar but among women >=40 years the incidence was much higher in France (97). 
The age standardized breast cancer incidence rate in Ghana was considerably 
lower at 14.16 per 100,000 compared to 129.89 per 100,000 in the US. Our estimate is 
also lower than the pooled West African breast cancer incidence rate of 24.2 per 100,000 
reported by Adeloye et al (30). While population based, the KCR only reports 
information from 5 of 6 facilities in Kumasi that provide breast cancer care.  However, 
data from KATH, the main cancer treatment hospital in Kumasi, is included in our 
sample so the registry likely captures the majority of cases in Kumasi (7, 67). Even when 
taking underestimation into account, the US incidence rate is still substantially higher 
compared to the Ghana rate. However, it is possible that over time the breast cancer 
incidence rates in Ghana will increase. Similar to other SSA countries, women in Ghana 
are living longer and their breast cancer risk profiles, especially among women in urban 
areas, are changing and becoming more similar to that of the US. For example, fertility 
rates in Ghana are declining (98), obesity rates are increasing (99) and life expectancy is 
increasing (100). The breast cancer risk profile in Ghana will continue to evolve and will 
likely lead to an increased incidence of breast cancer especially among older individuals. 
Research that evaluates the longitudinal changes in mean age at breast cancer diagnosis 
could help better understand the impact of these demographic shifts.   
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This study has several limitations. First, as previously stated, our estimate of 
incidence of breast cancer in Kumasi may have been underestimated. Second, while both 
SEER and KCR use ICD-O guidelines to identify incident cancer cases, the guideline 
versions are not identical. SEER uses the North American Association of Central Cancer 
Registries ICD-O guidelines while KCR uses the International Agency for Research on 
Cancer ICD-O guidelines (101, 102). In spite of these limitations, our study is the first to 
compare estimates from the only population-based registry in Ghana to nationally 
representative SEER data from the US. Our findings contribute valuable information on 
factors that may contribute to the persistent finding of the younger age at breast cancer 
diagnosis seen in Ghana.  
3.5 Conclusion 
 
Our study shows the importance of adjusting for differences in population age 
structures when comparing age at cancer diagnosis between countries. The younger age 
at diagnosis among women in Ghana compared to women in the US is partly due to 
population age structure differences. However, other factors such as breast cancer 
screening and differences in risk factor exposure among older women likely contribute to 
the age at diagnosis differences. Lastly, as the profile of breast cancer risk factors in 
Ghana becomes more like that of the US, the incidence of breast cancer in Ghana is 
expected to increase and may eventually reach current US levels. There is therefore an 
urgent need for evidence-based early detection and treatment interventions for the 




CHAPTER 4. MANUSCRIPT 3: USE OF SURGERY AND RADIATION FOR 
TRIPLE NEGATIVE BREAST CANCER: ASSOCIATION WITH SURVIVAL 
 
4.1 Introduction  
 
Triple negative breast cancer (TNBC) is a breast cancer subtype associated with 
an aggressive clinical course. It is characterized by lack of expression of estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2) (i.e. ER-, PR- and HER2-) (2, 3). TNBC accounts for 12-15% of all invasive 
breast cancer cases in the United States and is more likely to be diagnosed among Black 
and younger women (13, 103). Compared to other subtypes, TNBC has the highest 
recurrence rates, poorest survival rates and is usually higher grade, and has larger tumor 
size at diagnosis (3, 4). Because TNBC tumors do not have HER2, progesterone, or 
estrogen receptors, neither hormone therapy nor medications that work by blocking 
HER2 are used to treat patients with TNBC (13). This raises the question of whether the 
poor prognosis of TNBC warrants a more aggressive surgical approach and whether there 
is value in expanded use of radiation therapy among women with TNBC who receive 
mastectomy.  
Breast conserving surgery (BCS) and mastectomy are the two surgical options for 
breast cancer patients. Guidelines recommend that BCS should be followed by 
radiotherapy (i.e., breast conserving therapy, BCT) (104). While patients who receive 
mastectomy can receive radiotherapy, it is generally only recommended for cases with 
positive surgical margins or involved lymph nodes (26). The National Comprehensive 
Cancer Network (NCCN) surgical guidelines for breast cancer do not vary by breast 
cancer subtype (26). While randomized trials have shown that breast cancer patients 
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undergoing BCT or mastectomy have similar survival rates (105-107), to our knowledge, 
no randomized trials have compared different surgical treatments for TNBC.   
Several observational studies have explored use of surgery and radiotherapy for 
TNBC but have conflicting findings. Two population-based studies found that TNBC 
patients treated with BCT had superior breast cancer specific survival (BCSS) and overall 
survival (OS) compared to those who received mastectomy or mastectomy and 
radiotherapy (108, 109). However, the studies had only 3 years of follow-up and did not 
adjust for comorbidities that may impact surgical treatment for breast cancer (110). Two 
single-institution studies also found that TNBC patients who received BCT had higher 
OS compared to those who received mastectomy or mastectomy with radiotherapy (111, 
112). However, other single institution studies found no difference in OS among TNBC 
patients undergoing BCT or mastectomy (113, 114).  
Our study aims to examine whether the poor prognosis of TNBC necessitates a 
more aggressive surgical approach (i.e., mastectomy instead of BCS) and whether 
radiotherapy after BCS or mastectomy improves OS and BCSS. The goal is to inform 
guidelines for surgical treatment in this population.  
 




We used the National Cancer Institute (NCI)’s linked Surveillance Epidemiology 
and End Results (SEER)-Medicare database, which combines SEER population-based 
cancer registries data and Medicare claims. The SEER cancer registries provide 
population-based cancer surveillance data covering approximately 30% of the United 
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States (115). SEER data include patient sociodemographic and tumor characteristics, first 
course of treatment, and follow-up vital statistics. Medicare is a federally funded 
insurance program that provides coverage to 97% of the US population age 65 years and 
older. SEER-Medicare links 93% of eligible cancer cases to their Medicare claims (87). 
4.2.2 Study population 
 
The study cohort included women age 66 years or older diagnosed with stage I - 
III TNBC as their first or only cancer between 2010 and 2015. We required the women to 
be enrolled in Medicare fee-for-service for at least 12 months before and after cancer 
diagnosis or until death. This ensured that women have complete claims. We excluded 
women who did not have a known month of diagnosis and whose diagnosis was based on 
autopsy or death certificate (Appendix B).   
4.2.3 Patient characteristics 
 
Patient demographic characteristics obtained from Medicare included age at 
diagnosis, race, and comorbidity. Other sociodemographic variables included US census 
region and census median household income. We used the Charlson Comorbidity Score 
to calculate comorbidity and categorized it as 0,1,2 and 3+ (116). Patient-level tumor 
characteristics obtained from SEER included tumor size and stage at diagnosis.  
4.2.4 Treatment 
 
The four treatments considered were: 1) breast conserving surgery (BCS); 2) BCS 
and radiotherapy (i.e., breast conserving therapy, BCT); 3) mastectomy; and 4) 
mastectomy and radiotherapy. We used MedPAR, Outpatient, and Carrier files to identify 





Our outcomes were breast cancer-specific survival (BCSS) and overall survival 
(OS). Survival was defined as number of months from cancer diagnosis to death. Cause 
and date of death information were obtained from SEER. We used SEER's death date 
because it is linked to cause of death information. Observations were censored at the date 
of death or end of the observation period (December 31, 2015).  
4.2.6 Statistical Analysis 
 
We used Pearson's chi-square test to compare clinical and sociodemographic 
characteristics among the four treatment groups.  
Overall survival (OS) 
The Kaplan-Meier method was used to assess the cumulative incidence of all-
cause mortality by treatment. The log rank test was used to test differences between the 
survival curves. Cox proportional hazards regression was used to evaluate the effect of 
treatment method on OS controlling for tumor size, tumor stage, age at diagnosis, race, 
census tract median household income, US census region, and Charlson comorbidity 
score.   
Inverse Probability of Treatment Weighting (IPTW) 
Separately, we also used an IPTW Cox proportional hazards regression to 
evaluate the effect of treatment method on OS. To reduce treatment selection bias, we 
estimated propensity scores and used them in IPTW. Weighting patients by the inverse 
probability of the treatment received is another way to remove the association between 
the baseline covariates and treatment received (120). We used polytomous logistic 
regression to estimate the probability of treatment conditional on these baseline variables: 
tumor size, tumor stage, age at diagnosis, race, census tract median household income, 
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US census region, and Charlson comorbidity score. The inverse of each person's 
estimated probability of getting each treatment is the IPTW. We stabilized and truncated 
the IPTW to reduce variance induced by patients with extreme weights (121, 122). 
Stabilized IPTW was calculated by multiplying the IPTW by the estimated probability of 
receiving the treatment that each individual received (123). The stabilized IPTW were 
truncated at the 1st and 99th percentile (121). After IPTW, we used Pearson's chi-square to 
test the balance of the baseline variables and all variables were balanced.  
Breast cancer specific survival (BCSS) 
We used the Fine and Gray competing risk approach, where death due to breast 
cancer was the event of interest and death from other causes was considered a competing 
risk (124). We used a competing risk approach because individuals dying from other 
causes impacts the number of individuals who can die from breast cancer (125). 
Cumulative incidence functions (CIF) were used to estimate the incidence of death due to 
breast cancer by treatment. Gray's test was used to test differences between the CIFs. We 
used a Fine and Gray subdistribution hazard model to evaluate the effect of treatment 
method on BCSS while controlling for demographic and clinical characteristics. 
Separately, we also used an IPTW Fine and Gray subdistribution hazard model to 
evaluate the effect of treatment method on BCSS. The stabilized and truncated IPTW 
method is described above.  
We assessed the proportional hazard assumption in each analysis by specifying an 
interaction of treatment with survival time. The proportional hazard assumption was not 
violated.   
Treatments pair comparison and effect by stage 
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For each of the OS and BCSS models, we did pairwise comparisons to determine 
whether pairs of treatments differed, using Tukey's multiple comparison test to compare 
each pair and adjust for multiple comparisons. To examine whether the overall treatment 
effects were the same within each stage, we split the dataset by stage (I, II, and III) and 
re-did the analysis described above.  
Sensitivity analysis  
We conducted a series of sensitivity analyses to confirm that our findings did not 
vary based on analytic decisions. First, we confirmed that removing the <11 individuals 
who survived for less than one month after diagnosis did not impact model estimates. 
(We report the number of women excluded as "<11" to comply with the SEER-Medicare 
DUA which does not allow reporting of numbers less than 11 (126)). A second set of 
sensitivity analyses confirmed that using specific age and tumor size categories did not 
impact our results. We tested this by running the models described above with age as a 
continuous predictor, and categorizing the tumor sizes into smaller sub-categories (≤2 
cm, > 2 and ≤ 5 cm, > 5 and ≤ 10 cm, and >10cm). Third, we adjusted for chemotherapy 
receipt. 
All statistical tests were two-sided, and the level of significance was set at p < 
0.05. All analyses used SAS (PC SAS 9.4, SAS Institute, Inc., Cary, NC). This study was 
considered exempt by the Institutional Review Board at the University of Minnesota.  
4.2.7 Results 
 
Population description  
A total of 4598 women met our inclusion criteria (Appendix A). Of these, 94% 
(N = 4,333) received surgery (mastectomy or BCS). Of the 4,333, 49% (N=2,110) were 
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treated with BCT, 28% (N=1,219) with mastectomy, 14% (N=602) with mastectomy and 
radiotherapy (RT) and 9% (N=402) with BCS. All the sociodemographic and clinical 
characteristics differed by treatment group except race. However, all the characteristics 
were balanced when we used stabilized and truncated IPTWs (all p>0.05).  Compared to 
women who received other treatments, women who received BCT were younger, more 
likely to be stage I, had smaller tumors (≤2 cm), had lower Charlson comorbidity scores, 
were more likely to live in the Northeast US census region,and to be in the highest census 


















Table 7: Baseline patient demographic and clinical characteristics 









N % N % N  % N %   
Age at diagnosis 
(years) 
        
<0.0001 0.86 
66-74 135 33.58 1254 59.43 533 43.72 348 57.81 
  
75-84 139 34.58 716 33.93 474 38.88 185 30.73 
  
85+ 128 31.84 140 6.64 212 17.39 69 11.46 
  
Race 
        
0.35 0.72 
White  331 82.34 1746 82.75 994 81.54 499 82.89 
  
Black  50 12.44 283 13.41 156 12.80 77 12.79 
  
Other 21 5.22 81 3.84 69 5.66 26 4.32 
  
Region 
        
<0.0001 0.21 
Midwest 57 14.18 268 12.70 166 13.62 92 15.28 
  
Northeast 71 17.66 479 22.70 188 15.42 110 18.27 
  
South 107 26.62 486 23.03 376 30.84 165 27.41 
  
West 167 41.54 877 41.56 489 40.11 235 39.04 
  
Stage 
        
<0.0001 0.29 
I 199 49.50 1274 60.38 428 35.11 51 8.47 
  
II 173 43.03 731 34.64 623 51.11 231 38.37 
  
III 30 7.46 105 4.98 168 13.78 320 53.16 
  
Tumor size  
        
<0.0001 0.42 
≤2 cm 211 52.49 1370 64.93 481 39.46 120 19.93 
  
> 2 and ≤ 5 cm 164 40.80 665 31.52 586 48.07 277 46.01 
  








0 245 60.95 1569 74.36 810 66.45 443 73.59 
  
1 84 20.90 331 15.69 203 16.65 95 15.78 
  
2 30 7.46 111 5.26 118 9.68 38 6.31 
  
3+ 43 10.70 99 4.69 88 7.22 26 4.32 
  
Census tract median 
household income  
        
<0.0001 0.99 
<$40,000 87 21.64 346 16.40 281 23.05 111 18.44 
  
$40,001 - $50,000 69 17.16 280 13.27 191 15.67 105 17.44 
  
$50,001 - $60,000 60 14.93 325 15.40 197 16.16 95 15.78 
  
>$60,000 156 38.81 1055 50.00 462 37.90 257 42.69 
  
Missing 30 7.46 104 4.93 88 7.22 34 5.65 
  




The treatment groups differed significantly according to the Kaplan-Meier (KM) 
curves (p value <0.0001) (Figure ). The unadjusted KM curves show higher overall 
survival for women who received BCT compared to those who received BCS, 
mastectomy, or mastectomy + RT. Specifically, the 5-year overall survival rates for 
women who underwent BCT, mastectomy, mastectomy + RT, and BCS were 81.44%, 
57.16%, 47.18%,  and 51.07% respectively (Table 8).   
Findings from our multivariate and IPTW Cox proportional hazard models were similar 
(Table 9a, Appendix D). Here we present output from the multivariate Cox proportional 
hazard models. The three other treatments differed significantly from BCT after 
controlling for sociodemographic and clinical characteristics. Women who received BCS, 
or mastectomy or mastectomy + RT had significantly higher hazard of death compared to 
women who had BCT (hazard ratios (HR), 95% confidence interval (CI): 3.05, [2.43 - 
3.83]; 2.03, [1.70 - 2.43]; 1.74, [1.39 - 2.17] respectively) (Table 9a). In pairwise 
comparisons adjusted for multiple comparisons (Table 9b), five pairs of treatment 
differed significantly. Women who had BCS or mastectomy or mastectomy+ RT had 
significantly higher hazard of death compared to those who had BCT (adjusted p values 
<0.0001), and women who had BCS had significantly higher hazards of death compared 
to those who had mastectomy or mastectomy + RT (HR, adjusted p values: 1.50, 0.0008 
and 1.75, 0.0001, respectively). However, the hazard of death did not differ between 
those who had mastectomy vs mastectomy + RT (adjusted p value 0.39). 
Several factors were independent predictors of increased hazard of death (Table 
9a). Women with tumor size > 5 cm had higher hazard of death than those whose tumor 
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size was ≤2 cm (HR, 95% CI: 1.61, [1.23 - 2.10]). Women whose tumors were stage II or 
III had higher hazard of death than those whose tumors were stage I (HR, 95% CI: 2.03 
[1.54 - 2.68]; 4.10 [3.06 - 5.50] respectively). Lastly, older women (75-84 and 85+ years) 
had higher a hazard of death than younger women (66-74 years), women with higher 
Charlson comorbidity score had a higher hazard of death than those with lower scores, 
and women who lived in the Midwest and South US census regions had a higher hazard 
of death compared to those who lived in the West. 










5 year all-cause mortality 
cumulative incidence (%) 
81.44 57.16 47.18 51.07 
5 year breast cancer 
mortality cumulative 
incidence (%) 
8.35 18.56 36.02 20.44 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; HR  
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Table 9a: Multivariate Cox proportional hazards model predicting all-cause mortality  
 HR 95% CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 3.05 2.43 - 3.83 <0.0001 
Mastectomy 2.03 1.70 - 2.43 <0.0001 
Mastectomy + RT 1.74 1.39 - 2.17 <0.0001 
    
Tumor size  
   
≤2 cm 1.00 (Reference) 
> 2 and ≤ 5 cm 1.09 0.85 -1.41 0.49 
> 5 cm 1.61 1.23 - 2.10 0.0005 
Stage 
   
I 1.00 (Reference) 
II 2.03 1.54 - 2.68 <0.0001 
III 4.10 3.06 - 5.50 <0.0001 
Age at diagnosis (years) 
   
66-74 1.00 (Reference) 
75-84 1.52 1.30 - 1.77 <0.0001 
85+ 2.49 2.076-2.98 <0.0001 
Race 
   
White  1.00 (Reference) 
Black  0.89 0.72 - 1.09 0.24 
Other 0.98 0.71 - 1.35 0.90 
Charlson Comorbidity Score 
   
0 1.00 (Reference) 
1 1.26 1.05 -1.50 0.01 
2 1.49 1.18 - 1.89 0.001 
3+ 2.30 1.85 - 2.87 <0.0001 
Census tract median household 
income 
   
<40,000 1.00 (Reference) 
40,001 - 50,000 1.07 0.87 - 1.33 0.52 
50,001 - 60,000 1.00 0.80 - 1.24 0.97 
>60,000 0.90 0.75 - 1.09 0.29 
Missing 1.02 0.76 - 1.35 0.92 
Region 
   
Midwest 1.24 1.02 - 1.52 0.03 
Northeast 0.97 0.80 - 1.18 0.74 
South 1.21 1.02 - 1.44 0.03 
West 1.00 (Reference) 
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Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; HR 
– hazard ratio 
 
Table 9b: Pairwise Comparison - multivariate Cox proportional hazards model 
predicting all-cause mortality 
Treatment HR 95% CI P valuea 
BCS vs BCT 3.05 2.43 - 3.84 <0.0001 
BCS vs Mastectomy + RT 1.75 1.35 - 2.27 0.0001 
BCS vs Mastectomy 1.50 1.22 - 1.85 0.0008 
Mastectomy + RT vs BCT 1.74 1.39 - 2.17 <0.0001 
Mastectomy vs BCT 2.03 1.70 - 2.43 <0.0001 
Mastectomy vs Mastectomy + RT 1.17 0.96 - 1.42 0.39 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple comparisons 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; HR 
– hazard ratio. Covariates adjusted for include: tumor size, tumor stage, age at diagnosis, race, census tract 
median household income, US census region and Charlson comorbidity score.  
 
Breast cancer specific survival 
Gray’s test indicated that the treatment groups differed significantly in their CIFs 
(p value <0.0001) (Figure 5). The unadjusted CIFs showed lower cumulative incidence 
of death due to breast cancer for women who received BCT compared to those who 
received mastectomy, mastectomy + RT, or BCS. The 5-year cumulative incidence of 
death due to breast cancer for women who underwent BCT, mastectomy, mastectomy + 
RT, and BCS were 8.35%, 18.56%, 36.02%, and 20.44%, respectively (Table 8).   
As with overall survival, findings were similar from our multivariate and IPTW 
Fine and Gray subdistribution hazard models (Table 10a, Appendix E). Here we present 
output from the multivariate Fine and Gray subdistribution hazard model. The three other 
treatments differed significantly from BCT after controlling for sociodemographic and 
clinical characteristics. Women who had BCS or mastectomy or mastectomy + RT had 
significantly higher hazard of death due to breast cancer compared to women who had 
BCT (subdistribution hazard ratios (sHR), 95% CI: 2.67, [1.88 - 3.80]; 1.64, [1.26 - 2.12], 
1.95, [1.45 - 2.63]; respectively) (Table 10a) 
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In pairwise comparisons adjusted for multiple comparisons (Table 10b), four 
pairs of treatments differed. Women who had BCS, or mastectomy or  mastectomy+ RT 
had a significantly higher hazard of death due to breast cancer compared to those who 
had BCT (adjusted p values <0.0001, 0.001, <0.0001 respectively). Also, women who 
had BCS had significantly higher hazards of death due to breast cancer compared to those 
who had mastectomy (sHR, 1.63, adjusted p value 0.02). However, the hazard of death 
due to breast cancer did not differ significantly for those who had mastectomy vs 
mastectomy + RT or BCS vs mastectomy + RT (adjusted p values 0.56 and 0.40).  
Several factors were independent predictors of increased hazard of death due to 
breast cancer (Table 10a). Women with tumor size > 5 cm had higher hazard of death 
due to breast cancer than those whose tumor size was ≤2 cm (sHR 1.69, 95% CI [1.20 - 
2.39]). Women whose tumors were stage II or III had higher hazard of death due to breast 
cancer than those whose tumors were stage I (sHR, 95% CI: 3.04 [2.03 - 4.54]; 6.67 [4.38 
- 10.15] respectively). Lastly, women who were 85+ years had higher hazard of death due 
to breast cancer than those whose who were 66 -74 years.  
The overall pattern persisted when we divided the data into three subsets defined 
by stage. In stages I and II, BCT was associated with significantly higher OS and BCSS 
compared to BCS, mastectomy, or mastectomy + RT. However, among stage III women 
BCT, mastectomy, or mastectomy + RT did not differ significantly in BCSS while BCT 
and mastectomy + RT did not differ significantly in OS (Tables 11a, 11b, 12a, and 12b).  
With regard to the sensitivity analysis, excluding individuals who survived for 
less than a month, using age at diagnosis as continuous, smaller tumor size categories and 
 
62 
adjusting for chemotherapy did not change our findings notably (Appendices F,G, H, I, 
J, K, L, M, N, O, P, Q).   




Table 10a: Fine-Gray Subdistribution hazard model for breast cancer death  
 sHR 95% CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 2.67 1.88 - 3.80 <0.0001 
Mastectomy 1.64 1.26 - 2.12 0.0002 
Mastectomy + RT 1.95 1.45 - 2.63 <0.0001 
Tumor size  
   
≤2 cm 1.00 (Reference) 
> 2 and ≤ 5 cm 1.15 0.82 - 1.61 0.41 
> 5 cm 1.69 1.20 - 2.39  0.003 
Stage 
   
I 1.00 (Reference) 
II 3.04 2.03 - 4.54 <0.0001 
III 6.67 4.38 - 10.15 <0.0001 
Age at diagnosis (years) 
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66-74 1.00 (Reference) 
75-84 1.13 0.92 - 1.40 0.25 
85+ 1.51 1.16 - 1.97 0.003 
Race 
   
White  1.00 (Reference) 
Black  0.74 0.55 - 1.02 0.06 
Other 0.64 0.38 - 1.08 0.09 
Charlson Comorbidity Score 
   
0 1.00 (Reference) 
1 0.96 0.74 - 1.25 0.76 
2 1.30 0.94 - 1.80 0.12 
3+ 1.23 0.84 - 1.81 0.29 
Census tract median household 
income 
   
<40,000 1.00 (Reference) 
40,001 - 50,000 1.03 0.76 - 1.40 0.85 
50,001 - 60,000 1.03 0.76 - 1.39 0.85 
>60,000 0.85 0.65 - 1.11 0.22 
Missing 1.01 0.67 - 1.52  0.97 
Region 
   
Midwest 1.32 1.00 - 1.73 0.05 
Northeast 0.89 0.63 - 1.18 0.41 
South 1.26 1.00 - 1.60 0.05 
West 1.00 (Reference) 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; 
sHR Subdistribution hazard ratio 
 
Table 10b: Pairwise comparison - Fine-Gray Subdistribution hazard model for breast 
cancer death  
sHR 95% CI P valuea 
BCS vs BCT 2.67 1.88 - 3.80 <0.0001 
BCS vs Mastectomy + RT 1.37 0.93 - 2.03 0.40 
BCS vs Mastectomy 1.63 1.18 - 2.27 0.02 
Mastectomy + RT vs BCT 1.95 1.45 - 2.63 <0.0001 
Mastectomy vs BCT 1.64 1.26 - 2.12 0.001 
Mastectomy vs Mastectomy + RT 0.84 0.64 - 1.09 0.56 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple comparisons 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; 
sHR Subdistribution hazard ratio. Covariates adjusted for include: tumor size, tumor stage, age at 






Table 11a: Multivariate Cox proportional hazards model predicting all-cause mortality by stage  
Stage I Stage II Stage III 
 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Treatment 
         
BCT 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
BCS 2.69 1.82-3.97 <0.0001 2.61 1.88-3.62 <0.0001 6.50 3.5-11.93 <0.0001 
Mastectomy 1.84 1.31-2.58 0.0005 1.98 1.55-2.55 <0.0001 2.57 1.64-4.03 <0.0001 
Mastectomy 
+ RT 
3.34 1.76-6.34 0.0002 2.22 1.60-3.09 <0.0001 1.45 0.96-2.20 0.09 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; HR – hazard ratio.  
Covariates adjusted for include: tumor size, tumor stage, age at diagnosis, race, census tract median household income,  




Table 11b: Pairwise comparison - Multivariate Cox proportional hazards model predicting all-cause mortality by stage   
 
Stage I Stage II Stage III 
Treatment HR 95% CI P valuea  HR 95% CI  P valuea  HR 95% CI  P valuea  
BCS vs 
BCT 




0.80 0.4-1.60 0.93 1.17 0.81-1.70 0.84 4.47 2.71-7.39 <0.0001 
BCS vs 
Mastectomy 
1.46 0.98-2.19 0.25 1.31 0.98-1.76 0.26 2.53 1.54-4.16 0.002 
Mastectomy 
+ RT vs 
BCT 
3.34 1.76-6.34 0.001 2.22 1.60-3.09 <0.0001 1.45 0.96-2.20 0.3 
Mastectomy 
vs BCT 





0.55 0.29-1.06 0.28 0.89 0.66-1.20 0.88 1.77 1.33-2.35 0.0005 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple comparisons  
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; HR – hazard ratio.  
Covariates adjusted for include: tumor size, tumor stage, age at diagnosis, race, census tract median household income,  













Table 12a: Fine-Gray Subdistribution hazard model for breast cancer death by stage  
Stage I Stage II Stage III 
 
sHR 95% CI P value sHR 95% CI P value sHR 95% CI P value 
Treatment 
         
BCT 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
BCS 2.46 1.15 - 5.27 0.02 1.97 1.19-3.25 0.01 5.35 2.40-11.91 <0.0001 
Mastectomy 1.35 0.71 - 2.58 0.36 1.65 1.17-2.33 0.004 1.78 1.01-3.14 0.05 
Mastectomy 
+ RT 
4.87 1.88 - 12.58 0.001 2.25 1.48-3.42 0.0002 1.71 1.04-2.81 0.03 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; sHR Subdistribution hazard ratio.  
Covariates adjusted for include: tumor size, tumor stage, age at diagnosis, race, census tract median household income, 
 US census region and Charlson comorbidity score. 
Table 12b: Pairwise comparison - Fine-Gray Subdistribution hazard model for breast cancer death by stage  
Stage I Stage II Stage III 
Treatment sHR 95% CI P valuea sHR 95% CI P 
valuea  
sHR 95% CI  P 
valuea 
BCS vs BCT 2.46 1.15 - 5.27 0.09 1.97 1.19 - 3.25 0.04 5.35 2.40 - 11.91 0.0002 
BCS vs 
Mastectomy + RT 
0.51 0.17 - 1.48 0.60 0.88 0.50 - 1.53 0.97 3.12 1.59 - 6.15 0.01 
BCS vs 
Mastectomy 
1.82 0.82 - 4.05 0.45 1.19 0.75 - 1.90 0.88 3.01 1.50 - 6.01 0.01 
Mastectomy + RT 
vs BCT 
4.87 1.88 - 12.58 0.006 2.25 1.48 - 3.42 0.0009 1.71 1.04 - 2.81 0.14 
Mastectomy vs 
BCT 
1.35 0.71 - 2.58 0.80 1.65 1.17 - 2.33 0.02 1.78 1.01 - 3.14 0.19 
Mastectomy vs 
Mastectomy + RT 
0.28 0.10 - 0.74 0.06 0.74 0.49 - 1.10 0.43 1.04 0.72 - 1.51 0.99 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple comparisons Abbreviations: BCS – breast conserving surgery;  
BCT – breast conserving therapy; RT – radiotherapy; sHR Subdistribution hazard ratio. Covariates adjusted for include: tumor size, tumor stage, age at 
diagnosis, race, census tract median household income, US census region and Charlson comorbidity score.  
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Table 12b: Pairwise comparison - Fine-Gray Subdistribution hazard model for breast cancer death by stage  
Stage I Stage II Stage III 
Treatment sH
R 









95% CI  P 
valuea 
BCS vs BCT 2.46 1.15 - 5.27 0.09 1.97 1.19 - 3.25 0.04 5.35 2.40 - 11.91 0.0002 
BCS vs 
Mastectomy + RT 
0.51 0.17 - 1.48 0.60 0.88 0.50 - 1.53 0.97 3.12 1.59 - 6.15 0.01 
BCS vs 
Mastectomy 
1.82 0.82 - 4.05 0.45 1.19 0.75 - 1.90 0.88 3.01 1.50 - 6.01 0.01 
Mastectomy + RT 
vs BCT 
4.87 1.88 - 12.58 0.006 2.25 1.48 - 3.42 0.000
9 
1.71 1.04 - 2.81 0.14 
Mastectomy vs 
BCT 
1.35 0.71 - 2.58 0.80 1.65 1.17 - 2.33 0.02 1.78 1.01 - 3.14 0.19 
Mastectomy vs 
Mastectomy + RT 
0.28 0.10 - 0.74 0.06 0.74 0.49 - 1.10 0.43 1.04 0.72 - 1.51 0.99 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple comparisons Abbreviations:  
BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; sHR Subdistribution hazard ratio. 
 Covariates adjusted for include: tumor size, tumor stage, age at diagnosis, race, census tract median household income,  







This population-based study found that receiving BCT was associated with lower 
5-year cumulative incidence of all-cause and breast cancer specific death compared with 
mastectomy, mastectomy + RT, or BCS. These findings persisted in the multivariate and 
IPTW Cox proportional and Fine and Gray sub-distribution hazard models, in which 
individuals who had BCT had a lower hazard of all-cause and breast cancer specific 
mortality compared to those who had mastectomy, mastectomy + RT, or BCS. Similar 
patterns were observed in stage-specific analysis. BCT was associated with significantly 
higher OS and BCSS among women who had stage I or stage II disease. Although BCT 
did not differ significantly from mastectomy and mastectomy + RT in stage III, women 
who had BCT had better OS and BCSS than did women who received other treatments. 
We note that the analysis of stage III, where the sample size was only 623, had lower 
statistical power compared to stage I (N=1952) and stage II (N=1758).   
Based on results from randomized trials of surgical treatment for breast cancer, 
we would have expected women undergoing BCT or mastectomy to have similar hazards 
of death after accounting for clinical and demographic factors (105-107). Our finding of 
worse OS and BCSS for women receiving mastectomy than BCT suggests other factors 
could have differed between these groups of women that are not accounted for in our 
analyses. Possible factors include clinical factors such as margin status and non-clinical 
factors such as provider and patient preferences, which are not included in SEER-
Medicare (127). However, our findings are consistent with reports by Chen et al. (108) 
and Wang et al. (109), who studied TNBC. Another explanation for better survival rates 
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among those who had BCT compared to mastectomy is our outcomes of interest, OS and 
BCSS. Two observational studies found that among early-stage TNBC patients, BCT and 
mastectomy did not differ in terms of locoregional recurrence (112-114). Unfortunately, 
we could not assess recurrence in our study since SEER-Medicare does not include 
information about recurrence.  
Our study, which used the SEER-Medicare database, has several advantages over 
the Chen et al. and Wang et al studies, which used SEER data. These advantages include 
adjustment for patient comorbidity, which may impact the treatment received (110), 
accounting for competing risks of death from non-breast cancer causes, and longer 
follow-up time (5 compared to 3 years). Also, the sensitivity of SEER data in identifying 
radiation therapy is low, so using SEER-Medicare data allowed us to have more complete 
and accurate radiation information (128). Lastly, unlike previous studies on TNBC 
surgical and radiotherapy treatments (108, 109, 111-114), we assessed all surgical and 
radiotherapy combination options available to patients with TNBC, thus providing a more 
comprehensive understanding of the effectiveness of these treatments.  
The NCCN guidelines recommend that early-stage breast cancer patients receive 
radiation therapy following BCS because omitting radiotherapy after BCS is associated 
with increased risk of recurrence and mortality (129). However, 9% of patients in our 
study had BCS without radiation, which is similar to the proportion reported in previous 
studies (130, 131). As expected, in the multivariate analysis, women who received BCS 
had the lowest OS and BCSS. In our study, most women who received BCS without 
radiation had smaller tumors that were diagnosed at an earlier stage. Early-stage smaller 
tumors, which have a lower risk of recurrence, may have contributed to these women not 
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receiving radiation after BCS. However, given that radiation after BCS reduces 
recurrence even among women with better-prognosis tumors (e.g., early-stage and ER 
positive) (132) and the aggressive biology of TNBC, omission of radiotherapy after BCS 
is problematic and deserves attention.  
In our study, we did not observe any differences by race in survival outcomes 
after controlling for treatment, socio-demographic and clinical characteristics. These 
findings are consistent with several studies that found that among TNBC patients, racial 
groups did not differ in OS and BCSS after controlling for treatment and socio-
demographic characteristics (108, 109, 113, 133, 134). Although we did not find racial 
disparities in survival it is important to note that TNBC is more likely to be diagnosed 
among Black women and has a worse prognosis than other subtypes so there is still an 
urgent need for better treatment strategies for TNBC (3).  
This study had several limitations. First, we only included individuals who were 
at least 66 years old and enrolled in Medicare fee-for-service, so our findings may not 
generalize to a younger population or those enrolled in health maintenance organizations. 
Second, we were unable to assess recurrence because SEER does not collect this 
information. Third, we could not control for some clinical factors such as margin status 
and non-clinical factors such as patient and physician preferences, which may impact 
treatment receipt. We used IPTW and multivariate analysis to reduce selection bias for 
factors for which we could obtain data. Despite these limitations, our study, which used 
population-based data and is a nationally representative sample of elderly individuals, 
contributes valuable new information on the effectiveness of surgical treatment for 
TNBC in this population.  
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4.4 Conclusion  
 
This population-based cohort study of TNBC patients found that BCT is 
associated with higher OS and BCSS compared to BCS, mastectomy, or mastectomy and 
radiation. These findings persisted in the subsets of stage I and II patients. However, in 
the subset of stage III patients BCT, mastectomy, and mastectomy + RT did not differ 
significantly although the estimated treatment effects were of similar sizes.  
CHAPTER 5. OVERALL DISCUSSION 
 
This dissertation contributes to the existing body of knowledge on breast cancer 
incidence patterns, diagnosis, and treatment outcomes in Ghana and the US. Manuscript 1 
explores how women navigate the complex pathways to breast cancer diagnosis and 
treatment in Ghana and Manuscript 2 assesses factors contributing to the current breast 
cancer incidence patterns in Ghana. Manuscript 3 examines the optimal surgical 
treatment for women with triple negative breast cancer (TNBC) – the most aggressive 
breast cancer subtype that is also more likely to be diagnosed among Black women in the 
US and women in Ghana.  
In Manuscript 1 of this dissertation, we evaluated the breast cancer care 
continuum in Ghana from the perception of women with breast cancer. Patient’s 
perspectives and experiences are essential in the implementation of optimal healthcare 
interventions. Our study is the first to trace women’s pathways to breast cancer diagnosis 
and treatment in detail in Ghana. We found that women go through approximately seven 
steps from symptom detection to receiving allopathic breast cancer treatment in Ghana. 
Further, the pathway is not linear, with some women looping back repeatedly to earlier 
steps or skipping steps altogether. In addition, the women frequently move among 
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different management approaches including alternative therapy (e.g. faith healing and 
traditional medicine). Based on the findings from the interviews with women who have 
been diagnosed with breast cancer, we propose a comprehensive framework showing the 
pathways of care to breast cancer diagnosis and treatment. This framework can be used to 
identify locally relevant interventions that can be implemented to improve early detection 
and timely treatment of breast cancer in Ghana. Theoretical frameworks are important as 
they provide a systematic approach to understanding heath seeking behavior by building 
on existing knowledge (135-137). However, most existing frameworks do not include the 
role of alternative therapy providers and are therefore not applicable to settings where 
patients commonly seek care from these providers. Our study showed that alternative 
therapy providers play a major role in the breast cancer care continuum in Ghana. Our 
findings indicate that alternative therapy and allopathic medicine are not mutually 
exclusive contrary to the way they are currently presented in the literature. We 
recommend integration of alternative therapy providers in breast cancer diagnosis and 
management strategies. In an integrated system, alternative therapy providers can play a 
triage role, where they refer women with breast cancer related symptoms to allopathic 
medicine and offer psychosocial support as the women receive allopathic medicine. 
Additional research is warranted to assess how incorporating alternative therapy 
providers improves early detection of breast cancer, access and adherence to treatment. 
Findings from this study may be applicable to other countries where use of traditional 
medicine and faith healing is common. 
Manuscript 2 examined factors accounting for the younger age at diagnosis 
pattern that is evident in Ghana. Similar to previous studies comparing age at diagnosis in 
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sub-Saharan Africa (SSA) to North America and Europe, we found that women in Ghana 
were diagnosed at a younger age compared to women in the US. This phenomenon has 
previously been interpreted as women in SSA being at a higher risk for breast cancer 
compared to women in Europe and North America. However, our study refutes this 
notion; we showed that the younger age at diagnosis is partly due to population age 
structure differences. Using a US historical cohort (cases diagnosed 1975-1979) we 
showed that breast cancer screening is a second factor that contributes to the average 
lower mean age at diagnosis in Ghana. We argue that cohort effects, where older women 
in Ghana have more protective breast cancer risk profiles compared to older women in 
the US, is a third factor that may also contribute to this younger age diagnosis pattern in 
Ghana. Previous research has shown that breast cancer incidence is growing rapidly in 
SSA as the population ages and prevalence of risk factors increases, and incidence rates 
in SSA will likely reach those in Western countries (1). There is an urgent need for 
increased breast cancer control interventions across the cancer continuum from screening 
to treatment and palliative care. These interventions should also include tapping into the 
expertise of alternative therapy providers who are readily available and trusted by women 
in Ghana as evidenced in Manuscript 1.  More research is needed on the impact of the 
changing risk profile in Ghana on breast cancer incidence and mortality patterns. Further, 
Manuscript 2 highlights the necessary role of population-based cancer registries in 
understanding breast cancer incidence patterns. Using data from a population-based 
cancer registry in Ghana, we were able to identify potential factors contributing to the 
patterns of breast cancer in Ghana. Population-based cancer registries are a 
comprehensive source of data necessary to describe cancer burden, etiology, treatment 
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outcomes, and for monitoring and evaluating cancer management interventions. Out of 
46 countries in SSA, only 25 have a population-based cancer registry; thus, most breast 
cancer incidence estimates are based on data from the International Association of Cancer 
Registries (IARC) GLOBOCAN database (30, 138) However, due to lack of cancer 
incidence data in most SSA countries GLOBOCAN cancer incidence rates for some SSA 
countries are derived from rates from neighboring countries (139). Limited accurate 
population-based data is a hindrance for cancer control in SSA.  
Lastly, in Manuscript 3 we examined the optimal treatment for women with 
TNBC. Black women in the US and women in West African countries like Ghana are 
more likely to be diagnosed with TNBC. We found that women treated with BCS 
followed by radiotherapy (i.e breast conserving therapy (BCT)) had a better prognosis 
than those treated with mastectomy or mastectomy and radiotherapy. These findings 
suggest that TNBC is not a contraindication for breast conserving surgery (BCS) SEER-
Medicare is the only comprehensive source of population-based cancer data in the US 
that provides treatment information and allows for long-term follow up of cancer 
patients. Using these data, we provided real-world evidence that is essential for tailoring 
surgical treatment guidelines for TNBC patients in the US. Currently, high quality 
sources of cancer treatment and outcomes data do not exist in Ghana. Given the 
epidemiologic similarities of Ghanaian women and Black women in the US, findings 
from this study may also inform treatment guidelines for patients with TNBC in Ghana 
and/or form the basis for a more definitive study. However, in considering the 
applicability of these results to Ghana, it is important to note that the study population 
was at least 66 years old and differences in treatment resources between the two countries 
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might impact treatment recommendations. Lastly, we noted that our findings of worse 
survival outcomes among women receiving mastectomy compared to BCT might be due 
to factors that differed between the two groups that were not accounted for in our 
analysis. Further confirmation of our findings, in randomized clinical trials, is necessary.   
Findings from this dissertation are timely due to the rapidly rising burden of 
breast cancer in SSA and persistant disparities in the US. The framework from 
Manuscript 1 findings is useful for designing breast cancer control programs in Ghana 
and other LMICs with similar healthcare structures or health related belief systems. 
Manuscript 2 provides insight on the younger age at diagnosis patterns in Ghana and 
highlights the need for urgent action on breast cancer control in Ghana. Manuscript 3 
findings inform treatment guidelines for triple negative breast cancer and call for quality 





1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN 
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 
Cancer J Clin; 2021;0:1-41. 
2. Russnes HG, Lingjaerde OC, Borresen-Dale AL, Caldas C. Breast Cancer 
Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. Am J Pathol. 
2017;187(10):2152-62. 
3. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al. 
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-
negative disease: results from international breast cancer study group trials VIII and IX. J 
Clin Oncol. 2013;31(25):3083-90. 
4. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. 
Features of triple-negative breast cancer: Analysis of 38,813 cases from the national 
cancer database. Medicine. 2016;95(35). 
5. Fregene A, Newman LA. Breast cancer in sub-Saharan Africa: how does it relate 
to breast cancer in African-American women? Cancer. 2005;103(8):1540-50. 
6. Clegg-Lamptey JN, Aduful HK, Yarney J, Adu-Aryee NA, Vanderpuye V, 
Kyereh M, et al. Profile of breast diseases at a self-referral clinic in Ghana. West African 
journal of medicine. 2009;28(2):114-7. 
7. Laryea DO, Awuah B, Amoako YA, Osei-Bonsu E, Dogbe J, Larsen-Reindorf R, 
et al. Cancer incidence in Ghana, 2012: evidence from a population-based cancer 
registry. BMC Cancer. 2014;14:362-. 
8. Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, 
Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics 
Review, 1975-2016. National Cancer Institute; 2019. 
9. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, et al. 
Women age < or = 35 years with primary breast carcinoma: disease features at 
presentation. Cancer. 2005;103(12):2466-72. 
10. Azubuike SO, Muirhead C, Hayes L, McNally R. Rising global burden of breast 
cancer: the case of sub-Saharan Africa (with emphasis on Nigeria) and implications for 
regional development: a review. World J Surg Oncol. 2018;16(1):63. 
11. Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer 
epidemic: evidence from Africa. Breast Cancer Res. 2010;12(4):S8. 
12. Cody HS, 3rd. Current surgical management of breast cancer. Curr Opin Obstet 
Gynecol. 2002;14(1):45-52. 
13. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J 
Med. 2010;363(20):1938-48. 
14. Gangi A, Chung A, Mirocha J, Liou DZ, Leong T, Giuliano AE. Breast-
conserving therapy for triple-negative breast cancer. JAMA Surg. 2014;149(3):252-8. 
15. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, 
HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 
2009;101(10):736-50. 
16. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype 
classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929-43. 
 
77 
17. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-
specific incidence of breast cancer subtypes: understanding the black-white crossover. J 
Natl Cancer Inst. 2012;104(14):1094-101. 
18. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, 
menopause, and breast cancer risk: individual participant meta-analysis, including 118 
964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology. 
2012;13(11):1141-51. 
19. Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O, et al. Age at first 
birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic 
countries. International journal of cancer. 1990;46(4):597-603. 
20. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and 
incidence of cancer: a systematic review and meta-analysis of prospective observational 
studies. The Lancet. 2008;371(9612):569-78. 
21. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and 
hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological 
studies of 52,705 women with breast cancer and 108,411 women without breast cancer. 
Lancet. 1997;350(9084):1047-59. 
22. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic 
Density and the Risk and Detection of Breast Cancer. N Engl J Med. 2007;356(3):227-
36. 
23. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast 
cancer: collaborative reanalysis of individual data from 52 epidemiological studies 
including 58,209 women with breast cancer and 101,986 women without the disease. 
Lancet. 2001;358(9291):1389-99. 
24. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology. 
2007;25(11):1329-33. 
25. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative 
contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in 
Ashkenazi Women. Breast Cancer Res Treat. 2011;129(1):185-90. 
26. National Comprehensive Cancer Network National Comprehensive Cancer 
Network 2020 [Available from: https://www.nccn.org/guidelines/guidelines-
detail?category=1&id=1419 
27. Waks AG, Winer EP. Breast Cancer Treatment: A Review JAMA. 
2019;321(3):288-300. 
28. National Cancer Institute. Cancer Stat Facts: Female Breast Cancer: National 
Cancer Institute: Surveillance, Epidemiology, and End Results Program 2018 [Available 
from: https://seer.cancer.gov/statfacts/html/breast.html 
29. Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. Health 
and Racial Disparity in Breast Cancer. Adv Exp Med Biol. 2019;1152:31-49. 
30. Adeloye D, Sowunmi OY, Jacobs W, David RA, Adeosun AA, Amuta AO, et al. 
Estimating the incidence of breast cancer in Africa: a systematic review and meta-
analysis. Journal of Global Health. 2018;8(1):010419. 





32. Ohene-Yeboah M, Adjei E. Breast Cancer in Kumasi, Ghana. Ghana Medical 
Journal. 2012;46(1):8-13. 
33. Naku Ghartey Jnr F, Anyanful A, Eliason S, Mohammed Adamu S, Debrah S. 
Pattern of Breast Cancer Distribution in Ghana: A Survey to Enhance Early Detection, 
Diagnosis, and Treatment. Int J Breast Cancer. 2016;2016:3645308. 
34. Edmund DM, Naaeder SB, Tettey Y, Gyasi RK. Breast cancer in Ghanaian 
women: what has changed? Am J Clin Pathol. 2013;140(1):97-102. 
35. Stalsberg H, Adjei EK, Owusu-Afriyie O. No difference in the prevalence of 
benign breast changes between women from Ghana and Norway: an autopsy study. 
Breast Cancer Res Treat. 2015;151(1):177-82. 
36. Mensah A, Yarney J, Nokoe KS, Opoku S, Clegg-Lamptey JN. Survival 
Outcomes of Breast Cancer in Ghana: An Analysis of Clinicopathological Features2016. 
1-11 p. 
37. Thomas AS, Kidwell KM, Oppong JK, Adjei EK, Osei-Bonsu E, Boahene A, et 
al. Breast Cancer in Ghana: Demonstrating the Need for Population-Based Cancer 
Registries in Low- and Middle-Income Countries. Journal of global oncology. 
2017;3(6):765-72. 
38. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer 
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 
cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. 
39. Clegg-Lamptey J, Dakubo J, Attobra YN. Why Do Breast Cancer Patients Report 
Late or Abscond During Treatment in Ghana? A Pilot Study. Ghana Medical Journal. 
2009;43(3):127-31. 
40. Scherber S, Soliman AS, Awuah B, Osei-Bonsu E, Adjei E, Abantanga F, et al. 
Characterizing Breast Cancer Treatment Pathways in Kumasi, Ghana from Onset of 
Symptoms to Final Outcome: Outlook towards Cancer Control. Breast Dis. 
2014;34(4):139-49. 
41. Dedey F, Wu L, Ayettey H, Sanuade OA, Akingbola TS, Hewlett SA, et al. 
Factors Associated With Waiting Time for Breast Cancer Treatment in a Teaching 
Hospital in Ghana. Health Educ Behav. 2016;43(4):420-7. 
42. Kohler RE, Gopal S, Miller AR, Lee CN, Reeve BB, Weiner BJ, et al. A 
framework for improving early detection of breast cancer in sub-Saharan Africa: A 
qualitative study of help-seeking behaviors among Malawian women. Patient Educ 
Couns. 2017;100(1):167-73. 
43. Bonsu AB, Ncama BP. Recognizing and appraising symptoms of breast cancer as 
a reason for delayed presentation in Ghanaian women: A qualitative study. PLoS One. 
2019;14(1):e0208773. 
44. Agbeko AE, Arthur J, Bayuo J, Kaburi BB, Kyei I. Seeking healthcare at their 
‘right’ time; the iterative decision process for women with breast cancer. BMC Cancer. 
2020;20(1):1011. 
45. Scott SE, Walter FM, Webster A, Sutton S, Emery J. The model of pathways to 
treatment: conceptualization and integration with existing theory. Br J Health Psychol. 
2013;18(1):45-65. 
46. Bairati I, Fillion L, Meyer FA, Hery C, Larochelle M. Women's perceptions of 
events impeding or facilitating the detection, investigation and treatment of breast cancer. 
Eur J Cancer Care (Engl). 2006;15(2):183-93. 
 
79 
47. Moustakas C. Phenomenological research methods. Thousand Oaks, California 
1994 2020/07/28. 
48. Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. 
Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method 
Implementation Research. Adm Policy Ment Health. 2015;42(5):533-44. 
49. Grady MP, editor Qualitative and Action Research: A Practitioner 
Handbook1998. 
50. Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. 
Saturation in qualitative research: exploring its conceptualization and operationalization. 
Qual Quant. 2018;52(4):1893-907. 
51. Frie KG, Kamaté B, Traoré CB, Ly M, Kantelhardt EJ. Tackling Late-Stage 
Diagnosis of Breast Cancer Patients in Sub-Saharan Africa: A Case Study From Mali. 
Journal of global oncology. 2018;4(Supplement 2):64s-s. 
52. Grosse Frie K, Kamaté B, Traoré CB, Coulibaly B, Mallé B, Kantelhardt EJ. 
Health system organisation and patient pathways: breast care patients’ trajectories and 
medical doctors’ practice in Mali. BMC Public Health. 2019;19(1):204. 
53. Moodley J, Cairncross L, Naiker T, Momberg M. Understanding pathways to 
breast cancer diagnosis among women in the Western Cape Province, South Africa: a 
qualitative study. BMJ open. 2016;6(1):e009905. 
54. Moodley J, Cairncross L, Naiker T, Constant D. From symptom discovery to 
treatment - women's pathways to breast cancer care: a cross-sectional study. BMC 
Cancer. 2018;18(1):312-. 
55. Brown CA, Kohler RE, John O, Motswetla G, Mmalane M, Tapela N, et al. 
Multilevel Factors Affecting Time to Cancer Diagnosis and Care Quality in Botswana. 
Oncologist. 2018;23(12):1453-60. 
56. Stamatovic L, Vasovic S, Trifunovic J, Boskov N, Gajic Z, Parezanovic A, et al. 
Factors influencing time to seeking medical advice and onset of treatment in women who 
are diagnosed with breast cancer in Serbia. Psychooncology. 2018;27(2):576-82. 
57. QSR International Pty Ltd. (2018) NVivo (Version 12), [Available from 
 https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/home. 
58. Miles MB. Qualitative data analysis : a methods sourcebook: Third edition. 
Thousand Oaks, Califorinia : SAGE Publications, Inc., [2014]; 2014. 
59. Mays N, Pope C. Rigour and qualitative research. BMJ. 1995;311(6997):109-12. 
60. Carter N, Bryant-Lukosius D, DiCenso A, Blythe J, Neville AJ. The use of 
triangulation in qualitative research. Oncol Nurs Forum. 2014;41(5):545-7. 
61. Birt L, Scott S, Cavers D, Campbell C, Walter F. Member Checking: A Tool to 
Enhance Trustworthiness or Merely a Nod to Validation? Qual Health Res. 
2016;26(13):1802-11. 
62. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for 
Reporting Qualitative Research: A Synthesis of Recommendations. Acad Med. 
2014;89(9):1245-51. 
63. Abor P, Abekah-Nkrumah G, Abor J. An examination of Hospital Governance in 
Ghana. Leadersh Health Serv. 2008;21:47-60. 
64. James PB, Wardle J, Steel A, Adams J. Traditional, complementary and 




65. Yarney J, Donkor A, Opoku SY, Yarney L, Agyeman-Duah I, Abakah AC, et al. 
Characteristics of users and implications for the use of complementary and alternative 
medicine in Ghanaian cancer patients undergoing radiotherapy and chemotherapy: a 
cross- sectional study. BMC Complement Altern Med. 2013;13:16. 
66. Boateng MA, Danso-Appiah A, Turkson BK, Tersbøl BP. Integrating biomedical 
and herbal medicine in Ghana - experiences from the Kumasi South Hospital: a 
qualitative study. BMC Complement Altern Med. 2016;16:189. 
67. O'Brien KS, Soliman AS, Awuah B, Jiggae E, Osei-Bonsu E, Quayson S, et al. 
Establishing effective registration systems in resource-limited settings: cancer registration 
in Kumasi, Ghana. Journal of registry management. 2013;40(2):70-7. 
68. Arias D, Taylor L, Ofori-Atta A, Bradley EH. Prayer Camps and Biomedical Care 
in Ghana: Is Collaboration in Mental Health Care Possible? PLoS One. 
2016;11(9):e0162305. 
69. Furin J. The Role of Traditional Healers in Community-Based HIV Care in Rural 
Lesotho. J Community Health. 2011;36(5):849-56. 
70. Gureje O, Appiah-Poku J, Bello T, Kola L, Araya R, Chisholm D, et al. Effect of 
collaborative care between traditional and faith healers and primary health-care workers 
on psychosis outcomes in Nigeria and Ghana (COSIMPO): a cluster randomised 
controlled trial. The Lancet. 2020;396(10251):612-22. 
71. Krah E, de Kruijf J, Ragno L. Integrating Traditional Healers into the Health Care 
System: Challenges and Opportunities in Rural Northern Ghana. J Community Health. 
2018;43(1):157-63. 
72. Centers for Disease Control and Prevention. What Is Breast Cancer Screening? 
Available from: https://www.cdc.gov/cancer/breast/basic_info/screening.htm  
73. Devi BC, Tang TS, Corbex M. Reducing by half the percentage of late-stage 
presentation for breast and cervix cancer over 4 years: a pilot study of clinical 
downstaging in Sarawak, Malaysia. Ann Oncol. 2007;18(7):1172-6. 
74. Mena M, Wiafe-Addai B, Sauvaget C, Ali IA, Wiafe SA, Dabis F, et al. 
Evaluation of the impact of a breast cancer awareness program in rural Ghana: a cross-
sectional survey. International journal of cancer. 2014;134(4):913-24. 
75. Opoku SY, Benwell M, Yarney J. Knowledge, attitudes, beliefs, behaviour and 
breast cancer screening practices in Ghana, West Africa. The Pan African Medical 
Journal. 2012;11:28. 
76. Zelle SG, Nyarko KM, Bosu WK, Aikins M, Niëns LM, Lauer JA, et al. Costs, 
effects and cost-effectiveness of breast cancer control in Ghana. Trop Med Int Health. 
2012;17(8):1031-43. 
77. Kantelhardt EJ, Muluken G, Sefonias G, Wondimu A, Gebert HC, Unverzagt S, et 
al. A Review on Breast Cancer Care in Africa. Breast Care. 2015;10(6):364-70. 
78. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. 
Elevated breast cancer mortality in women younger than age 40 years compared with 
older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 
2009;208(3):341-7. 
79. Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, et al. 
Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African 








81. United States Census. 2010 Census Summary File 1, 2011. 
https://www2.census.gov/programs-surveys/decennial/2010/technical-
documentation/complete-tech-docs/summary-file/sf1.pdf. 
82. Bidoli E, Virdone S, Hamdi-Cherif M, Toffolutti F, Taborelli M, Panato C, et al. 
Worldwide Age at Onset of Female Breast Cancer: A 25-Year Population-Based Cancer 
Registry Study. Sci Rep. 2019;9(1):14111. 
83. Verdial FC, Etzioni R, Duggan C, Anderson BO. Demographic changes in breast 
cancer incidence, stage at diagnosis and age associated with population-based 
mammographic screening. J Surg Oncol. 2017;115(5):517-22. 
84. Centers for Disease Control and Prevention. Mammography. Available from: 
https://www.cdc.gov/nchs/fastats/mammography.htm. 
85. Amoako YA, Awuah B, Larsen-Reindorf R, Awittor FK, Kyem G, Ofori-Boadu 
K, et al. Malignant tumours in urban Ghana: evidence from the city of Kumasi. BMC 
Cancer. 2019;19(1):267. 
86. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). 
2018. Available from: https://seer.cancer.gov/about/factsheets/SEER_Overview.pdf 
87. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-
Medicare data: content, research applications, and generalizability to the United States 
elderly population. Med Care. 2002;40(8 Suppl):Iv-3-18. 
88. National Cancer Institute. Registry Groupings in SEER Data and Statistics. 
Available from: https://seer.cancer.gov/registries/terms.html 
89. National Cancer Institute.  Download U.S. Population Data - 1969-2019. 
Available from: https://seer.cancer.gov/popdata/download.html  
90. Ghana Statistical Services. https://statsghana.gov.gh/index.php 
91. Stapleton SM, Oseni TO, Bababekov YJ, Hung Y, Chang DC. Race/ethnicity and 
age distribution of breast cancer diagnosis in the united states. JAMA Surgery. 
2018;153(6):594-5. 
92. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age 
standardization of rates: A new WHO standard. 2001. 
93. American Cancer Society. History of ACS Recommendations for the Early 
Detection of Cancer in People without Symptoms. Available from:  
https://www.cancer.org/health-care-professionals/american-cancer-society-prevention-
early-detection-guidelines/overview/chronological-history-of-acs-recommendations.html 
94. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast Cancer Screening in 
Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Ann Intern Med. 
2017;166(5):313-23. 
95. Gaisie S. Fertility Trend in Ghana. African Population Studies (ISSN: 0850-5780) 
Vol 20 Num 2. 2013;20. 
96. Smith SK, Ahmed B. A demographic analysis of the population growth of states, 
1950-1980. J Reg Sci. 1990;30(2):209-27. 
97. Corbex M, Bouzbid S, Boffetta P. Features of breast cancer in developing 
countries, examples from North-Africa. Eur J Cancer. 2014;50(10):1808-18. 
 
82 
98. Blanc AK, Grey S. Greater than expected fertility decline in Ghana: untangling a 
puzzle. J Biosoc Sci. 2002;34(4):475-95. 
99. Lartey ST, Magnussen CG, Si L, Boateng GO, de Graaff B, Biritwum RB, et al. 
Rapidly increasing prevalence of overweight and obesity in older Ghanaian adults from 
2007-2015: Evidence from WHO-SAGE Waves 1 & 2. PLoS One. 2019;14(8):e0215045. 
100. Mba CJ. Population Ageing in Ghana: Research Gaps and the Way Forward. J 
Aging Res. 2010;2010:672157. 
101. National Cancer Institute Surveillance and End Results Program. ICD-O-3 
Coding Materials  [Available from: https://seer.cancer.gov/icd-o-3/. 
102. International Association of Cancer Registries. International Classification of 
Diseases for Oncology (ICD-O). 
http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&i
d=100&Itemid=577 
103. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of 
estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-
negative invasive breast cancer, the so-called triple-negative phenotype: a population-
based study from the California cancer Registry. Cancer. 2007;109(9):1721-8. 
104. Warburton R, Chiu CG, Roberts A, et al. Current surgical management of breast 
cancer. BCMJ 2018; 60:92-98. 
105. Lichter AS, Lippman ME, Danforth DN, Jr., d'Angelo T, Steinberg SM, deMoss 
E, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II 
carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 
1992;10(6):976-83. 
106. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. 
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with 
radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-32. 
107. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. 
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, 
Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast 
Cancer. N Engl J Med. 2002;347(16):1233-41. 
108. Chen Q-X, Wang X-X, Lin P-Y, Zhang J, Li J-J, Song C-G, et al. The different 
outcomes between breast-conserving surgery and mastectomy in triple-negative breast 
cancer: a population-based study from the SEER 18 database. Oncotarget. 
2016;8(3):4773-80. 
109. Wang SE, Sun Yd, Zhao SJ, Wei F, Yang G. Breast conserving surgery (BCS) 
with adjuvant radiation therapy showed improved prognosis compared with mastectomy 
for early staged triple negative breast cancer patients Running title: BCS had better 
prognosis than mastectomy for early TNBC patients. Math Biosci Eng. 2019;17(1):92-
104. 
110. Zhou J, Enewold L, Zahm SH, Jatoi I, Shriver C, Anderson WF, et al. Breast 
conserving surgery versus mastectomy: the influence of comorbidities on choice of 
surgical operation in the Department of Defense health care system. Am J Surg. 
2013;206(3):393-9. 
111. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased 
risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer 
 
83 
treated with modified radical mastectomy without adjuvant radiation therapy compared 
with breast-conserving therapy. J Clin Oncol. 2011;29(21):2852-8. 
112. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, 
Litton JK, et al. Triple-Negative Breast Cancer Is Not a Contraindication for Breast 
Conservation. Ann Surg Oncol. 2011;18(11):3164. 
113. Zumsteg ZS, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, et al. Breast-
Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in 
Women with T1-2N0 Triple-Negative Breast Cancer. Ann Surg Oncol. 
2013;20(11):3469-76. 
114. Parker CC, Ampil F, Burton G, Li BDL, Chu QD. Is breast conservation therapy a 
viable option for patients with triple-receptor negative breast cancer? Surgery. 
2010;148(2):386-91. 
115. Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The 
Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward 
Strengthening the Critical Relationship. The American journal of surgical pathology. 
2016;40(12):e94-e102. 
116. National Cancer Institute Division of Cancer Control & Population Sciences. 
SEER-Medicare: Selecting the Appropriate Comorbidity SAS Macro. Available from 
https://healthcaredelivery.cancer.gov/seermedicare/considerations/calculation.html.  
117. Gabriela Dieguez  CF, David Rotter. The cost burden of blood cancer care. A 
longitudinal analysis of commercially insured patients diagnosed with blood cancer. 
2018. 
118. Gibson DC, Chou L-N, Raji MA, Baillargeon JG, Kuo Y-F. Opioid Prescribing 
Trends in Women Following Mastectomy or Breast-Conserving Surgery Before and 
After the 2014 Federal Reclassification of Hydrocodone. The oncologist. 
2020;25(4):281-9. 
119. Killelea BK, Long JB, Chagpar AB, Ma X, Soulos PR, Ross JS, et al. Trends and 
clinical implications of preoperative breast MRI in Medicare beneficiaries with breast 
cancer. Breast Cancer Res Treat. 2013;141(1):155-63. 
120. Austin PC, Stuart EA. Moving towards best practice when using inverse 
probability of treatment weighting (IPTW) using the propensity score to estimate causal 
treatment effects in observational studies. Stat Med. 2015;34(28):3661-79. 
121. Cole SR, Hernán MA. Constructing inverse probability weights for marginal 
structural models. Am J Epidemiol. 2008;168(6):656-64. 
122. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of Stabilized 
Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its 
Confidence Intervals. Value Health. 2010;13(2):273-7. 
123. Pezzi A, Cavo M, Biggeri A, Zamagni E, Nanni O. Inverse probability weighting 
to estimate causal effect of a singular phase in a multiphase randomized clinical trial for 
multiple myeloma. BMC Med Res Methodol. 2016;16(1):150. 
124. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a 
Competing Risk. Journal of the American Statistical Association. 1999;94(446):496-509. 
125. Bolch CA, Chu H, Jarosek S, Cole SR, Elliott S, Virnig B. Inverse probability of 
treatment-weighted competing risks analysis: an application on long-term risk of urinary 
adverse events after prostate cancer treatments. BMC Med Res Methodol. 2017;17(1):93. 
 
84 
126. National Cancer Institute SEER-Medicare Data Use Agreement (DUA). Available 
from: https://healthcaredelivery.cancer.gov/seermedicare/obtain/seerdua.pdf.  
127. Gu J, Groot G, Boden C, Busch A, Holtslander L, Lim H. Review of Factors 
Influencing Women's Choice of Mastectomy Versus Breast Conserving Therapy in Early 
Stage Breast Cancer: A Systematic Review. Clin Breast Cancer. 2018;18(4):e539-e54. 
128. Noone A-M, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. 
Comparison of SEER Treatment Data With Medicare Claims. Med Care. 2016;54(9):e55-
e64. 
129. Vinh-Hung V, Verschraegen C, Project FTBCS. Breast-Conserving Surgery With 
or Without Radiotherapy: Pooled-Analysis for Risks of Ipsilateral Breast Tumor 
Recurrence and Mortality. JNCI: Journal of the National Cancer Institute. 
2004;96(2):115-21. 
130. Longacre C, Neprash H, Shippee N, Tuttle T, Virnig B. Travel, Treatment 
Choice, and Survival Among Breast Cancer Patients: A Population-Based Analysis. 
Women's Health Reports. 2021;2:1-10. 
131. Guidolin K, Lock M, Vogt K, McClure JA, Winick-Ng J, Vinden C, et al. 
Recurrence and mortality after breast-conserving surgery without radiation. Curr Oncol. 
2019;26(6):380-8. 
132. Viani GA, Stefano EJ, Afonso SL, De Fendi LI, Soares FV, Leon PG, et al. 
Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma 
in situ: a meta-analysis of randomized trials. Radiat Oncol. 2007;2:28. 
133. Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Racial differences in outcomes of 
triple-negative breast cancer. Breast Cancer Res Treat. 2013;138(1):281-9. 
134. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong Y-N, Edge SB, et al. 
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor 
Characteristics and Sociodemographic and Treatment Factors. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 
2015;33(20):2254-61. 
135. Walter F, Webster A, Scott S, Emery J. The Andersen Model of Total Patient 
Delay: a systematic review of its application in cancer diagnosis. J Health Serv Res 
Policy. 2012;17(2):110-8. 
136. Scott S, Walter F. Studying Help‐Seeking for Symptoms: The Challenges of 
Methods and Models2010. 531-47 p. 
137. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, et al. The Aarhus 
statement: improving design and reporting of studies on early cancer diagnosis. Br J 
Cancer. 2012;106(7):1262-7. 
138. Omonisi AE, Liu B, Parkin DM. Population-Based Cancer Registration in Sub-
Saharan Africa: Its Role in Research and Cancer Control. JCO Global Oncology. 
2020(6):1721-8. 
139. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. 
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and 







Appendix A: Interview Guide 
Section 1 
Introduction:  
Thank you for taking the time to talk to us about your journey seeking care 
 for breast cancer. My name is (Research Assistant name) and this is Waruiru 
 who is a student. Waruiru is working on research on the pathway to breast 
 cancer care among women in Ghana. We hope that the information gathered 
 from these interviews will help us better understand Ghanaian women’s journey 
 in seeking care for breast cancer from symptom detection to treatment and ways to ensure 
 that women get the best breast cancer care soonest possible. 
We will be recording the session because we do not want to miss any of your input. 
 We know you have helpful comments and we cannot write fast enough to 
 get them all down. We will not include any names or other identifiable information  
and what you say is confidential. Do you have any questions for me? Do 
 I have your permission to start the interview? 
Icebreaker: 
What Ghanaian food do you enjoy making?  
Main question:  
Please tell us the story of your journey from when you detected  
bodily change to when you started receiving breast cancer treatment  
Below are the probes (only ask the probes if the patient did not  
provide this information)  
1. Please tell us the first change or symptom that you noticed in  
2. your breast? 
- Time of discovery  (date & year) 
- Please tell us how you discovered the symptom or change in  
- your breast?  
- What happened after the discovery? 
- What did you think the symptom was?  
- Was it a serious issue to you? 
- So what did you do after the discovery 
o Did you get any treatment related to the symptom? 
3. Please tell us what you thought was the cause of the breast symptoms?  
-  Why did you think that was the cause?  
4. Please tell us if you shared the information with anybody? 
- Who?  
- Why? 
- When?  
- What did the person tell you?  
5. Did you see a doctor about the symptom?  
- Where (facility)? Why this facility? 
 
86 
- When (date & year)?  
- Why early? Or why delay? 
- What happened at the hospital?  
- What did the doctor say?  
- What did the doctor do for you?  
- Any labs? 
- Any referral? Why, when and to where? 
6. Please can you share with me the journey from when your symptom  
7. was assessed by the doctor to diagnosis?  
o What happened? 
o What were you asked to do?  
o The various investigations requested 
o Where did you do each of these?  
o cost 
8. Were you actually told that you have breast cancer?  
- When (Date) 
- Who informed you?  And Where?  
- How did you feel 
- So what happened next? 
- Who did you inform about your breast cancer? Why? 
- Any referral? By who? When and to where?  
9. So have you received any treatment so far? 
- What type?  
- When did you start? 
- How long have you been on treatment? 
10. Please can you share with me your experiences with the treatment so far  
11. and if there are factors that have impacted your ability to continue receiving 
treatment 
- Side effects 
- Cost 
- Any insurance 
- Any labs 
- How long it takes you to get to the facility 
- Any support?  
12. (Research Assistant summarize what the patient said to check accuracy) 
13. Is there any other thing you may want to share with us. 
 
Thank you for taking the time to share your journey with us. We now have a  
short survey that we would like you to fill. Please let us know if any question  












2 What is your marital 
status 
☐   Single                                       
☐   Married/Partnered/Cohabiting  
☐   Widowed/Divorced/Separated  
 
3 What is your highest 
level of education? 
☐   Primary school                             
☐   High school                                   
☐   Technical college diploma          
☐   Bachelor degrees                         
☐   Masters                                          
☐   Other (specify)                              
4 What is your religion  ☐   Christian                              
☐   Muslim                                   
☐   Other (specify)                              
5 Are you employed? ☐   Yes  
☐   No (SKIP to question 7) 
6 If employed, who do 
you work for?  
☐  Government 
☐  Self-employed 
☐  Other (specify) 
7 Do you have health 
insurance? 
☐  Yes  
☐   No  
8 Has anyone in your 
family ever had 
cancer? 
☐   Yes  
☐   No (SKIP to question 11) 
9 Your relation to them?  ☐   Father  
☐   Mother  
☐   Grandmother 
☐   Grandfather  
☐   Sibling 
☐   Child  
☐   Husband 
10 If anyone in your 
family has had cancer, 
what type of cancer 
did they have?  
☐   Breast  




Appendix B. Cohort inclusion and exclusion criteria  
 




Total breast cancer cases in SEER-




Restrict to breast cancer is the only 
cancer or first of many 
204861 20567 9.12 
Restrict to female 203205 1656 0.81 
Restrict to not diagnosed by autopsy 
or death certificate 
202017 1188 0.58 
Restrict to known month of diagnosis 201267 750 0.37 
Restrict to triple negative breast 
cancer (TNBC) 
16010 185257 92.05 
Restrict to age 66 years and older at 
diagnosis 
9205 6805 42.50 
Restrict to Medicare fee for service 
(Parts A and B) and no HMO 
enrollment 12 months prior and post 
diagnosis or until death 
5194 4011 43.57 
Restrict to stage I-III 4598 596 11.47 
 
Appendix C: Radiation and surgery codes 
 
Treatment  Code type Specific codes 
Radiation  ICD 9 
diagnosis 
codes  





92.2, 92.20, 92.21, 92.22, 92.23, 92.24, 92.25, 
92.26, 92.27, 92.28, 92.29, 






3E0F304, 3E0F704, 3E0F804, 3E0G304, 
3E0G704, 3E0G804, 3E0H304, 3E0H704, 
3E0H804, 3E0J304, 3E0J704, 3E0J804, 
3E0L304, 3E0L704, 3E0M304, 3E0M704, 
3E0Y304, 3E0Y704, DBY07ZZ, DBY17ZZ, 
DBY27ZZ, DBY57ZZ,  DBY67ZZ, DBY77ZZ, 
DDY57ZZ, DDY77ZZ, DMY07ZZ, DMY17ZZ, 
DWY27ZZ, DWY37ZZ, D7040ZZ, D7050ZZ, 
D7060ZZ, DB000ZZ, DB010ZZ, DB020ZZ, 
DB050ZZ, DB060ZZ, DB070ZZ, DD050ZZ, 
DD070ZZ, DH060ZZ, DH080ZZ, DM000ZZ, 
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DM010ZZ, DW020ZZ, DW030ZZ, D71497Z, 
D71498Z, D71499Z,  D7149BZ, D7149CZ, 
D7149YZ, D714B7Z, D714B8Z, D714B9Z, 
D714BBZ, D714BCZ, D714BYZ, D71597Z, 
D71598Z, D71599Z, D7159BZ, D7159CZ, 
D7159YZ, D715B7Z, D715B8Z, D715B9Z, 
D715BBZ, D715BCZ, D715BYZ, D71697Z, 
D71698Z, D71699Z, D7169BZ, D7169CZ, 
D7169YZ, D716B7Z, D716B8Z, D716B9Z, 
D716BBZ, D716BCZ, D716BYZ, DB1097Z, 
DB1098Z, DB1099Z, DB109BZ, DB109CZ, 
DB109YZ, DB10B7Z, DB10B8Z, DB10B9Z, 
DB10BBZ, DB10BCZ, DB10BYZ, DB1197Z, 
DB1198Z, DB1199Z, DB119BZ, DB119CZ, 
DB119YZ, DB11B7Z, DB11B8Z, DB11B9Z, 
DB11BBZ, DB11BCZ, DB11BYZ, DB1297Z, 
DB1298Z, DB1299Z, DB129BZ, DB129CZ, 
DB129YZ, DB12B7Z, DB12B8Z, DB12B9Z, 
DB12BBZ, DB12BCZ, DB12BYZ, DB1597Z, 
DB1598Z, DB1599Z, DB159BZ, DB159CZ, 
DB159YZ, DB15B7Z, DB15B8Z, DB15B9Z, 
DB15BBZ, DB15BCZ, DB15BYZ, DB1797Z, 
DB1798Z, DB1799Z, DB179BZ, DB179CZ, 
DB179YZ, DB17B7Z, DB17B8Z, DB17B9Z, 
DB17BBZ, DB17BCZ, DB17BYZ, DD1597Z, 
DD1598Z, DD1599Z, DD159BZ, 
DD159CZ,  DD159YZ, DD15B7Z, DD15B8Z, 
DD15B9Z, DD15BBZ, DD15BCZ, DD15BYZ, 
DD1797Z, DD1798Z, DD1799Z, DD179BZ, 
DD179CZ, DD179YZ, DD17B7Z, DD17B8Z, 
DD17B9Z, DD17BBZ, DD17BCZ, DD17BYZ, 
DM1097Z, DM1098Z, DM1099Z, DM109BZ, 
DM109CZ, DM109YZ, DM10B7Z, DM10B8Z, 
DM10B9Z, DM10BBZ, DM10BCZ, 
DM10BYZ, DM1197Z, DM1198Z, DM1199Z, 
DM119BZ, DM119CZ, DM119YZ, DM11B7Z, 
DM11B8Z, DM11B9Z, DM11BBZ, DM11BCZ, 
DM11BYZ, DW1297Z, DW1298Z, DW1299Z, 
DW129BZ, DW129CZ, DW129YZ, DW12B7Z, 
DW12B8Z, DW12B9Z, DW12BBZ, 
DW12BCZ, DW12BYZ, DW1397Z, DW1398Z, 
DW1399Z, DW139BZ, DW139CZ, DW139YZ, 
DW13B7Z, DW13B8Z, DW13B9Z, DW13BBZ, 
DW13BCZ, DW13BYZ, D7041ZZ, D7042ZZ, 
D7051ZZ, D7052ZZ, DB001ZZ, DB002ZZ, 
DB011ZZ, DB012ZZ, DB021ZZ, DB022ZZ, 
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DB051ZZ, DB052ZZ, DB071ZZ, DB072ZZ, 
DD051ZZ, DD052ZZ, DD071ZZ, DD072ZZ, 
DM001ZZ, DM002ZZ, DM011ZZ, DM012ZZ, 
DW021ZZ, DW022ZZ, D7043ZZ, D7053ZZ, 
D7063ZZ,  DB003ZZ, DB013ZZ, DB023ZZ, 
DB053ZZ, DB073ZZ, DD053ZZ, DD073ZZ, 
DM003ZZ, DM013ZZ, DW023ZZ, D7044ZZ, 
D7045ZZ, D7054ZZ, D7055ZZ, DB004ZZ, 
DB005ZZ,  DB014ZZ, DB015ZZ, DB024ZZ, 
DB025ZZ, DB054ZZ, DB055ZZ, DB074ZZ, 
DB075ZZ, DD054ZZ, DD055ZZ, DD074ZZ, 
DD075ZZ, DM004ZZ, DM005ZZ, DM014ZZ, 
DM015ZZ, DW024ZZ, DW025ZZ, 0BH001Z, 
0BH031Z, 0BH041Z, 0BH071Z, 0BH081Z, 
0BHK01Z, 0BHK31Z, 0BHK41Z, 0BHK71Z, 
0BHK81Z, 0BHL01Z, 0BHL31Z, 0BHL41Z, 
0BHL71Z, 0BHL81Z, 0DHP01Z, 0DHP31Z, 
0DHP41Z, 0DHP71Z, 0DHP81Z, 0HHT01Z, 
0HHT31Z, 0HHT71Z, 0HHT81Z,  0HHU01Z, 
0HHU31Z,  0HHU71Z, 0HHU81Z, 0HHV01Z, 
0HHV31Z, 0HHV71Z, 0HHV81Z, 0HHW01Z, 
0HHW31Z,  0HHW71Z, 0HHW81Z, 
0HHWX1Z, 0HHX01Z, 0HHX31Z, 0HHX71Z, 
0HHX81Z, 0HHXX1Z, 0WH801Z, 0WH831Z, 
0WH841Z, 0WH901Z, 0WH931Z, 0WH941Z, 
0WHB01Z, 0WHB31Z, 0WHB41Z, 0WHQ01Z 
0WHQ31Z, 0WHQ41Z, 0WHQ71Z, 0WHQ81Z, 
0XH401Z, 0XH431Z, 0XH441Z, 0XH501Z, 
0XH531Z, 0XH541Z, CW73NZZ, CW73YZZ, 
D7Y4FZZ, D7Y5FZZ, DBY0FZZ, DBY1FZZ, 
DBY2FZZ, DBY5FZZ, DBY7FZZ, DDY5FZZ, 
DDY7CZZ, DDY7FZZ, DMY0FZZ, 
DMY1FZZ, DWY2FZZ 
D7043Z0, D7053Z0, D7063Z0, DB003Z0, 





19296, 19297, 32701, 61793, 61796, 61797, 
61798, 61799, 61800, 63620, 63621, 32701, 
61793, 77373, G0173, G0251, G0339, G0340, 
0082T, 77371-77399 , 77401-77427, 77427-
77499, 77520-77525, 77750-77799  
G0173, G0174, G0242, G0243, G0251, G0338-







Mastectomy ICD 9 
procedure 
codes 
85.33, 85.34, 85.4, 85.41, 85.43, 85.45, 85.47, 




0H0T0JZ, 0H0U0JZ, 0HTT0ZZ, 0HTU0ZZ, 
0KTH0ZZ, 0KTJ0ZZ, 0H0V0JZ, 0HTV0ZZ, 




19140, 19180, 19182, 19200, 19220, 19240, 












0H5T3ZZ, 0H5T8ZZ, 0H5U3ZZ, 0H5U8ZZ, 
0H5V3ZZ, 0H5V8ZZ, 0HBT0ZZ, 0HBT3ZZ, 
0HBT7ZZ, 0HBT8ZZ, 0HBU0ZZ, 0HBU3ZZ, 
0HBU7ZZ, 0HBU8ZZ, 0HBV0ZZ, 0HBV3ZZ, 
0HBV7ZZ, 0HBV8ZZ, 0HBY0ZZ, 0HBY3ZZ, 
0HBY7ZZ, 0HBY8ZZ, 0HTY0ZZ, 0H5W0ZZ, 
0H5W3ZZ, 0H5W7ZZ, 0H5W8ZZ, 0H5WXZZ, 
0H5X0ZZ, 0H5X3ZZ, 0H5X7ZZ, 0H5X8ZZ, 
0H5XXZZ, 0HBW0ZZ, 0HBW3ZZ, 
0HBW7ZZ, 0HBW8ZZ, 0HBWXZZ, 
0HBX0ZZ, 0HBX3ZZ, 0HBX7ZZ, 0HBX8ZZ, 




38790, 38792, 38900, 78800, 78801 
 
 
Appendix D: IPTW cox proportional hazards model predicting 
 all-cause mortality  
HR 95% CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 3.44 2.56 - 4.62 <0.0001 
Mastectomy 1.91 1.57 - 2.32 <0.0001 
Mastectomy + RT 2.21 1.65 - 2.97 <0.0001 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; HR hazard ratio 
 
Appendix E: IPTW Fine-Gray Subdistribution hazard model for  




sHR 95% CI P 
value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 3.25 2.45 - 4.32 <0.001 
Mastectomy 1.65 1.31 - 2.08 <0.001 
Mastectomy + RT 2.59 2.02 - 3.32 <0.001 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; RT – radiotherapy; 
sHR Subdistribution hazard ratio 
 
Appendix F: Multivariate Cox proportional hazards model predicting all-cause 
mortality after excluding those who survived for only one month  
HR 95%CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 2.99 2.37 - 3.76 <0.0001 
Mastectomy 2.00 1.67 - 2.40 <0.0001 
Mastectomy + RT 1.76 1.41 - 2.20 <0.0001 
Tumor size  
   
≤2 cm 1.00 (Reference) 
> 2 and ≤ 5 cm 1.09 0.85 - 1.41 0.49 
> 5 cm 1.58 1.20 - 2.06 0.0009 
Stage 
   
I 1.00 (Reference) 
II 2.06 1.55 - 2.72 <0.0001 
III 4.10 3.05 - 5.51 <0.0001 
Age at diagnosis (years) 
  
66-74 1.00 (Reference) 
75-84 1.52 1.30 - 1.77 <0.0001 
85+ 2.49 2.08 - 2.98 <0.0001 
Race 
   
White  1.00 (Reference) 
Black  0.89 0.73 - 1.09 0.26 
Other 0.94 0.67 - 1.30 0.70 
Charlson Comorbidity Score 
  
0 1.00 (Reference) 
1 1.25 1.05 - 1.50 0.01 
2 1.49 1.18 - 1.89 0.001 






   
<$40,000 1.00 (Reference) 
$40,001 - $50,000 1.07 0.86 - 1.33 0.54 
$50,001 - $60,000 0.98 0.79 - 1.23 0.88 
>$60,000 0.91 0.75 - 1.10 0.33 
Missing 1.03 0.78 - 1.37 0.83 
Region 
   
Midwest 1.24 1.016-1.516 0.03 
Northeast 0.96 0.785-1.165 0.66 
South 1.20 1.006-1.426 0.04 
West 1.00 (Reference) 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; HR – hazard ratio 
Appendix G: Pairwise comparison - Multivariate Cox proportional hazards 
 model predicting all-cause mortality after excluding those who survived for a 
month or less 
Treatment HR 95% CI P valuea  
BCS vs BCT 2.99 2.37 - 3.76 <0.0001 
BCS vs Mastectomy + RT 1.70 1.31 - 2.20 0.0004 
BCS vs Mastectomy 1.49 1.21 - 1.84 0.0011 
Mastectomy + RT vs 
BCT 
1.76 1.41 - 2.20 <0.0001 
Mastectomy vs BCT 2.00 1.67 - 2.40 <0.0001 
Mastectomy vs 
Mastectomy + RT 
1.14 0.94 - 1.38 0.57 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple  
comparisons Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; HR – hazard ratio. Covariates adjusted for include: tumor size, tumor stage,  
age at diagnosis, race, census tract median household income, US census region and  
Charlson comorbidity score.  
 
Appendix H: Fine-Gray Subdistribution hazard model for breast  
cancer death after excluding those who survived for a month or less  
sHR 95% CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 2.65 1.86 - 3.77 <0.0001 
Mastectomy 1.63 1.25 - 2.11 0.0002 
Mastectomy + RT 1.96 1.46 - 2.64 <0.0001 
Tumor size  
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≤2 cm 1.00 (Reference) 
> 2 and ≤ 5 cm 1.15 0.82 - 1.60 0.43 
> 5 cm 1.69 1.20 - 2.40 0.003 
Stage 
   
I 1.00 (Reference) 
II 3.10 2.07 - 4.65 <0.0001 
III 6.69 4.38 - 10.20 <0.0001 
Age at diagnosis (years) 
   
66-74 1.00 (Reference) 
75-84 1.11 0.90 - 1.38 0.33 
85+ 1.51 1.16 - 1.97 0.002 
Race 
   
White  1.00 (Reference) 
Black  0.73 0.53 - 1.00 0.05 
Other 0.60 0.35 - 1.03 0.07 
Charlson Comorbidity 
Score 
   
0 1.00 (Reference) 
1 0.95 0.73 - 1.24 0.71 
2 1.27 0.92 - 1.77 0.15 
3+ 1.21 0.82 - 1.79 0.33 
Census tract median 
household income 
   
<40,000 1.00 (Reference) 
40,001 - 50,000 1.02 0.75 - 1.38 0.92 
50,001 - 60,000 1.04 0.77 - 1.40 0.81 
>60,000 0.83 0.64 - 1.09 0.19 
Missing 1.01 0.67 - 1.52 0.97 
Region 
   
Midwest 1.32 1.01 - 1.74 0.05 
Northeast 0.89 0.67 - 1.18 0.4 
South 1.25 0.98 - 1.58 0.07 
West 1.00 (Reference) 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; sHR Subdistribution hazard ratio 
 
Appendix I: Pairwise comparison - Fine-Gray Subdistribution hazard  
model for breast cancer death after excluding  
those who survived for a month or less  
sHR 95% CI P valuea 
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BCS vs BCT 2.65 1.86 - 3.77 <0.0001 
BCS vs Mastectomy + RT 1.35 0.91 - 2.00 0.44 
BCS vs Mastectomy 1.63 1.17 - 2.26 0.02 
Mastectomy + RT vs BCT 1.96 1.46 - 2.64 <0.0001 
Mastectomy vs BCT 1.63 1.25 - 2.11 0.001 
Mastectomy vs Mastectomy + RT 0.83 0.63 - 1.08 0.52 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple  
comparisons Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; sHR Subdistribution hazard ratio. Covariates adjusted for include: tumor size,  
tumor stage, age at diagnosis, race, census tract median household income, US census region  
and Charlson comorbidity score.  
 
Appendix J: Continuous age and tumor size broke further - Multivariate  
Cox proportional hazards model predicting all-cause mortality   
 
HR 95%CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 2.93 2.33 - 3.68 <0.0001 
Mastectomy 1.98 1.65 - 2.37 <0.0001 
Mastectomy + RT 1.73 1.38 - 2.16 <0.0001 
Tumor size  
   
≤1 cm 1.00 (Reference) 
> 1 and ≤ 2 cm 1.64 1.21 - 2.22 0.002 
> 2 and ≤ 5 cm 1.62 1.13 - 2.33 0.009 
> 5 and ≤ 10 cm 2.47 1.68 - 3.64 <0.0001 
> 10 cm 2.16 1.39 - 3.36 0.0007 
Stage 
   
I 1.00 (Reference) 
II 1.94 1.47 - 2.58 <0.0001 
III 3.86 2.87 - 5.18 <0.0001 
Age at diagnosis (years) 
   
1 year 1.05 1.04 - 1.06 <0.0001 
Race 
   
White  1.00 (Reference) 
Black  0.91 0.74 - 1.11 0.36 
Other 0.97 0.70 - 1.34 0.85 
Charlson Comorbidity 
Score 
   
0 1.00 (Reference) 
1 1.25 1.05 - 1.50 0.01 
2 1.47 1.16 - 1.86 0.002 
3+ 2.27 1.82 - 2.83 <0.0001 
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Census tract median 
household income 
   
<40,000 1.00 (Reference) 
40,001 - 50,000 1.07 0.87 - 1.33 0.52 
50,001 - 60,000 0.99 0.80 - 1.24 0.96 
>60,000 0.90 0.75 - 1.09 0.28 
Missing 0.98 0.74 - 1.30 0.89 
Region 
   
Midwest 1.24 1.01 - 1.51 0.04 
Northeast 0.97 0.80 - 1.18 0.79 
South 1.22 1.03 - 1.45 0.02 
West 1.00 (Reference) 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; HR – hazard ratio 
 
Appendix K: Pairwise comparison - Continuous age and tumor size broke  
further - Multivariate Cox proportional hazards model predicting all-cause 
mortality 
Treatment HR 95% CI P valuea 
BCS vs BCT 2.93 2.33 - 3.68 <0.0001 
BCS vs Mastectomy + RT 1.70 1.31 - 2.20 0.0004 
BCS vs Mastectomy 1.48 1.21 - 1.8 0.001 
Mastectomy + RT vs BCT 1.73 1.38 - 2.16 <0.0001 
Mastectomy vs BCT 1.98 1.65 - 2.37 <0.0001 
Mastectomy vs Mastectomy + 
RT 
1.14 0.94 - 1.39 0.53 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple  
comparisons Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; 
 RT – radiotherapy; HR-  hazard ratio. Covariates adjusted for include: tumor size, tumor stage,  
age at diagnosis, race, census tract median household income, US census region and  
Charlson comorbidity score.  
 
Appendix L: Continuous age and tumor size broke further - Fine-Gray 
Subdistribution hazard model for breast cancer death  
sHR 95% CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 2.67 1.89 - 
3.78 
<0.0001 
Mastectomy 1.63 1.26 - 
2.11 
0.0002 
Mastectomy + RT 1.94 1.44 - 
2.61 
<0.0001 
Tumor size  
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≤1 cm 1.00 (Reference) 
> 1 and ≤ 2 cm 2.04 1.19 - 
3.50 
0.01 
> 2 and ≤ 5 cm 2.06 1.17 - 
3.62 
0.01 
> 5 and ≤ 10 cm 2.96 1.64 - 
5.36 
0.0003 




   
I 1.00 (Reference) 
II 2.92 1.96 - 
4.35 
<0.0001 
III 6.38 4.21 - 
9.66 
<0.0001 
Age at diagnosis (years) 
   




   
White  1.00 (Reference) 
Black  0.75 0.55 - 
1.03 
0.07 





   
0 1.00 (Reference) 
1 0.95 0.73 - 
1.23 
0.69 
2 1.30 0.93 - 
1.80 
0.12 
3+ 1.23 0.84 - 
1.81 
0.29 
Census tract median 
household income 
   
<40,000 1.00 (Reference) 
40,001 - 50,000 1.03 0.76 - 
1.39 
0.87 
50,001 - 60,000 1.04 0.77 - 
1.40 
0.81 
>60,000 0.85 0.65 - 
1.11 
0.22 






   
Midwest 1.31 1.00 - 
1.73 
0.05 
Northeast 0.89 0.67 - 
1.18 
0.42 
South 1.27 1.01 - 
1.61 
0.04 
West 1.00 (Reference) 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; sHR Subdistribution hazard ratio  
 
Appendix M: Pairwise comparison - Continuous age and tumor size broke 
 further - Fine-Gray Subdistribution hazard model for breast cancer death  
sHR 95% CI P valuea 
BCS vs BCT 2.67 1.89 - 3.78 <0.0001 
BCS vs Mastectomy + RT 1.38 0.93 - 2.04 0.37 
BCS vs Mastectomy 1.64 1.19 - 2.27 0.01 
Mastectomy + RT vs BCT 1.94 1.44 - 2.61 <0.0001 
Mastectomy vs BCT 1.63 1.26 - 2.11 0.001 
Mastectomy vs Mastectomy 
+ RT 
0.83 0.64 - 1.10 0.57 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple 
 comparisons Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; 
 RT – radiotherapy; sHR Subdistribution hazard ratio. Covariates adjusted for include: tumor size,  
tumor stage, age at diagnosis, race, census tract median household income, US census region  
and Charlson comorbidity score.  
 
Appendix N: Multivariate Cox proportional hazards model predicting  
all-cause mortality including chemotherapy adjustment  
 HR 95% CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 2.80 2.22 - 3.51 <0.0001 
Mastectomy 1.92 1.60 - 2.30 <0.0001 
Mastectomy + RT 1.84 1.47 - 2.31 <0.0001 
    
Tumor size  
   
≤2 cm 1.00 (Reference) 
> 2 and ≤ 5 cm 1.08 0.84 -1.39 0.54 
> 5 cm 1.52 1.17 – 1.99 0.002 
Stage 
   
I 1.00 (Reference) 
II 2.29 1.73 – 3.04 <0.0001 
III 4.92 3.65 – 6.62 <0.0001 
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Age at diagnosis (years) 
   
66-74 1.00 (Reference) 
75-84 1.28 1.09 - 1.51 0.003 
85+ 1.81 1.48 - 2.22 <0.0001 
Race 
   
White  1.00 (Reference) 
Black  0.88 0.72 - 1.07 0.21 
Other 0.96 0.70 - 1.33 0.82 
Charlson Comorbidity 
Score 
   
0 1.00 (Reference) 
1 1.24 1.04 -1.49 0.02 
2 1.43 1.13 - 1.81 0.003 
3+ 2.17 1.74 - 2.71 <0.0001 
Census tract median 
household income 
   
<40,000 1.00 (Reference) 
40,001 - 50,000 1.03 0.83 - 1.28 0.78 
50,001 - 60,000 0.96 0.77 - 1.20 0.72 
>60,000 0.89 0.74 - 1.08 0.22 
Missing 0.98 0.73 - 1.30 0.87 
Region 
   
Midwest 1.19 0.97 - 1.45 0.09 
Northeast 0.96 0.79 - 1.17 0.69 
South 1.17 0.98 - 1.39 0.08 
West 1.00 (Reference) 
Chemotherapy   
Yes 1.00 (Reference) 
No 1.71 1.45 – 2.02 <0.0001 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy; 
 RT – radiotherapy; HR – hazard ratio 
 
Appendix O: Pairwise Comparison - multivariate Cox proportional  
hazards model predicting all-cause mortality including chemotherapy  
adjustment 
Treatment HR 95% CI P valuea 
BCS vs BCT 2.80 2.22 - 3.51 <0.0001 
BCS vs Mastectomy + RT 1.52 1.17 – 1.97 0.009 
BCS vs Mastectomy 1.46 1.19 - 1.80 0.002 
Mastectomy + RT vs BCT 1.84 1.47 - 2.31 <0.0001 
Mastectomy vs BCT 1.92 1.60 - 2.30 <0.0001 
 
100 
Mastectomy vs Mastectomy 
+ RT 
1.05 0.85 - 1.27 0.98 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple 
 comparisons Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; HR – hazard ratio. Covariates adjusted for include: tumor size, tumor stage,  
age at diagnosis, race, census tract median household income, US census region, Charlson  
comorbidity score and chemotherapy.  
 
Appendix P: Fine-Gray Subdistribution hazard model for breast cancer death 
including chemotherapy adjustment  
 sHR 95% CI P value 
Treatment 
   
BCT 1.00 (Reference) 
BCS 2.61 1.83 - 3.73 <0.0001 
Mastectomy 1.61 1.24 - 2.09 0.0004 
Mastectomy + RT 1.97 1.47 - 2.66 <0.0001 
Tumor size  
   
≤2 cm 1.00 (Reference) 
> 2 and ≤ 5 cm 1.15 0.82 - 1.60 0.42 
> 5 cm 1.67 1.18 - 2.36 0.004 
Stage 
   
I 1.00 (Reference) 
II 3.11 2.07 - 4.68 <0.0001 
III 6.91 4.50 - 10.61 <0.0001 
Age at diagnosis (years) 
   
66-74 1.00 (Reference) 
75-84 1.10 0.88 - 1.36 0.41 
85+ 1.41 1.05 - 1.90 0.02 
Race 
   
White  1.00 (Reference) 
Black  0.74 0.54 - 1.01 0.06 
Other 0.64 0.38 - 1.07 0.09 
Charlson Comorbidity 
Score 
   
0 1.00 (Reference) 
1 0.96 0.74 - 1.24 0.74 
2 1.29 0.93 - 1.78 0.13 
3+ 1.21 0.82 - 1.78 0.34 
Census tract median 
household income 
   
<40,000 1.00 (Reference) 
40,001 - 50,000 1.02 0.75 - 1.40 0.88 
50,001 - 60,000 1.02 0.76 - 1.38 0.89 
 
101 
>60,000 0.84 0.64 - 1.10 0.21 
Missing 1.00 0.66 - 1.51  0.99 
Region 
   
Midwest 1.31 0.99 - 1.72 0.05 
Northeast 0.89 0.67 - 1.18 0.41 
South 1.26 0.99 - 1.59 0.05 
West 1.00 (Reference) 
Chemotherapy   
Yes 1.00 (Reference) 
No 1.12 0.88 – 1.43 0.36 
Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; sHR Subdistribution hazard ratio 
 
Appendix Q. Pairwise comparison -  Fine-Gray Subdistribution hazard model 
 for breast cancer death including chemotherapy adjustment  
sHR 95% CI P valuea 
BCS vs BCT 2.61 1.83 - 3.73 <0.0001 
BCS vs Mastectomy + RT 1.33 0.89 – 1.98 0.51 
BCS vs Mastectomy 1.62 1.17 - 2.27 0.02 
Mastectomy + RT vs BCT 1.97 1.47 - 2.66 <0.0001 
Mastectomy vs BCT 1.61 1.24 - 2.09 0.002 
Mastectomy vs Mastectomy 
+ RT 
0.82 0.62 - 1.07 0.46 
a The Tukey multiple comparison test was used to compare each pair and adjust for multiple 
 comparisons Abbreviations: BCS – breast conserving surgery; BCT – breast conserving therapy;  
RT – radiotherapy; sHR Subdistribution hazard ratio. Covariates adjusted for include: tumor size, 
 tumor stage, age at diagnosis, race, census tract median household income, US census region,  
Charlson comorbidity score and chemotherapy.  
 
 
 
 
 
 
